Podcasts about emory university school

The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:1. Orforglipron for maintenance of body weight reduction  - Nature Medicine2026. Discussion by:Guest:Joe Gonella, MD Resident - Abington Family Medicine Residency Program Jefferson Health2. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN) Lancet 2026.  Discussion by: Guest:Neil Skolnik, MDProfessor of Family and Community MedicineSidney  Kimmel  Medical College Thomas Jefferson UniversityAssociate Director - Family Medicine Residency ProgramJefferson Health – Abington3. Survival and Recurrence with GLP-1 Receptor Agonists in Breast Cancer" – JAMA Network Open Discussion by:Guest:Neil Skolnik, MDProfessor of Family and Community MedicineSidney  Kimmel  Medical College Thomas Jefferson UniversityAssociate Director - Family Medicine Residency ProgramJefferson Health – Abington4. In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia.   NEJM 2026 Discussion by:Guest:Alex Sauer, MD Resident - Abington Family Medicine Residency ProgramJefferson HealthMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. This Podcast Episode does not offer CME/CE Credit. Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

Welcome to Fertility & Sterility Roundtable, hosted by Dr. Emily Barnard and Dr. Ben Peipert! Each week, we will host a discussion with the authors of "Views and Reviews" and "Fertile Battle" articles published in a recent issue of Fertility & Sterility.  Today, we will be discussing the Fertile Battle episode from the April 2026 edition of Fertility and Sterility entitled "Is Concurrent Gestational Surrogacy an Ethical Practice?" Concurrent surrogacy involves two gestational carriers being engaged simultaneously—or whose pregnancies overlap—to allow a single intended parent or couple to have children born without the usual spacing between births  Dr. Michelle Bayefsky is a second year Reproductive Endocrinology and Infertility fellow at the Icahn School of Medicine at Mount Sinai. She has written a book and more than 30 peer-reviewed papers on issues related to reproductive ethics and fertility preservation. She is currently a member of the ASRM Ethics Committee. For the purposes of this discussion, Dr. Bayefsky authored the Pro side of the argument that concurrent gestational surrogacy is an ethical practice.  Dr. Caroline Violette is a second year Reproductive Endocrinology & Infertility Fellow at Brown University. Prior to fellowship, Dr. Violette obtained her medical degree from Emory University School of Medicine and completed her residency in Obstetrics and Gynecology at the University of Southern California. Her research interests include oncofertility and addressing healthcare disparities related to access to fertility treatment in the United States. For the purposes of this discussion, Dr. Violette authored the "con" side of the argument that these concurrent surrogacy arrangements are unethical.  Dr. Arthur Caplan is a Professor and founding head of the Division of Medical Ethics at NYU School of Medicine in New York City. Dr. Caplan has served on a number of national and international committees, including chair of the Advisory Committee to the United Nations on Human Cloning, a member of the advisory committee to the International Olympic Committee on genetics and gene therapy, and co-director of the Joint Council of Europe/United Nations Study on Trafficking in Organs and Body Parts. He is the author or editor of thirty-five books and over 890 papers in peer reviewed journals. Dr. Caplan authored the pro side of the argument.  Read the Fertile Battle from Volume 125, Issue 4 p598-604 in the April 2026 issue View Fertility and Sterility at https://www.fertstert.org/  

Kate Mihevc Edwards, PT, DPT, OCS, physical therapist and board-certified orthopedic specialist who practices running medicine.  She has over 16+ years of experience working with high performers, CEOs, runners and endurance athletes of all levels, from recreational athletes to Olympians. She is the founder of Precision Performance Running Medicine Clinic in Atlanta, GA, RUNsource app.And co-host of the Interdisciplinary Case MIlesPodcast. She is an integral part of the multidisciplinary team supporting Atlanta Track ClubElite. Dr. Edwards has served as adjunct faculty at Emory University School of Medicine and is a published author and speaker, contributing extensively to education, research and the advancement of sports medicine for runners.  #drdanamzallag, #drdanpodcast, #Happinessjourneywithdrdan,#ddanmotivation, #inspiringinterviews, #drdancbt, #drdantherapy,#drdancoaching, #drdanhappiness,  

In this special EMS One-Stop update, Rob Lawrence is joined by returning guest Dr. Alex Isakov to break down the rapidly developing Andes Hantavirus outbreak linked to the expedition cruise ship MV Hondius. What began as a handful of unexplained respiratory illnesses aboard a South Atlantic voyage has evolved into an internationally monitored infectious disease event involving multiple countries, quarantine operations, public health investigations and the repatriation of exposed passengers to specialized containment facilities in the United States. | MORE: Hantavirus outbreak aboard cruise ship sends Americans to biocontainment quarantine units Dr. Isakov is professor of emergency medicine at Emory University School of Medicine and executive director of the Emory Office of Critical Event Preparedness and Response (CEPAR). He also serves as EMS lead for the National Emerging Special Pathogens Training and Education Center (NETEC), where he helps lead national preparedness efforts for high-consequence infectious diseases. In the episode, he explains how Andes Hantavirus differs from other hantaviruses already present in North America because it is capable of person-to-person transmission in limited circumstances. The discussion covers transmission dynamics, incubation periods, PPE recommendations, public health monitoring and why experts continue to assess the overall public risk as low. Listeners are also directed toward the excellent educational resource hub on preparedness and response available through NETEC Hantavirus Resources. Episode timeline 00:00 – Introduction to the Special Edition. Rob Lawrence introduces the emergency update format and welcomes Dr. Alex Isakov to discuss the emerging Andes Hantavirus outbreak. 00:50 – Understanding hantaviruses. Dr. Isakov explains the difference between common North American hantaviruses and Andes Virus, emphasizing the rare person-to-person transmission capability. 03:13 – The cruise ship incident. Discussion of the outbreak aboard the MV Hondius, including onboard transmission concerns, severe illness development and international evacuation efforts. 05:16 – U.S. monitoring and quarantine. Review of quarantine operations in Nebraska and ongoing public health monitoring of exposed American passengers. 07:21 – Incubation and EMS risk assessment. Dr. Isakov outlines the prolonged incubation period and explains why frontline EMS encounters remain unlikely. 11:17 – PPE guidance for EMS personnel. Specific PPE recommendations are reviewed, including standard, contact and airborne precautions with eye protection. 13:17 – Looking ahead to World Cup 2026. The discussion turns to international travel, mass gatherings and why clinicians must maintain awareness of rare infectious diseases tied to travel history. 14:32 – EMS and public health resources. Dr. Isakov directs listeners to CDC, WHO and NETEC resources for ongoing guidance and EMS-specific updates.

In this North America episode of the World PICU Awareness Week 2026 podcast, leading experts explore how leadership directly influences caregiver wellbeing and burnout in pediatric intensive care. Through practical examples and evidence-based insights, the discussion highlights the importance of listening to teams, addressing system-level challenges, and fostering a culture where wellbeing is embedded into everyday practice. From leadership behaviors to institutional support, this episode emphasizes a clear message: sustainable PICU care starts with how we lead. HOST Leah Harris Professor and Chair, Department of Pediatrics Dell Medical School at the University of Texas at Austin - Dell Children's Hospital GUEST Asha N Shenoi Professor, Associate Dean University of Kentucky Will Border Chief Physician Wellness Officer, Director of Noninvasive Cardiac Imaging Children's Healthcare of Atlanta and Emory University School of Medicine Wendy Quiroz Nasser Pediatric Nurse Practitioner Baylor College of Medicine (BCM) | Texas Children's Hospital DATE Initial publication date: May 7, 2026 TRANSCRIPTS English - https://cdn.bfldr.com/D6LGWP8S/as/jcbg3x5x35f4sb3wct2kx89w/North_America_26_transcript Spanish - https://cdn.bfldr.com/D6LGWP8S/as/jcbg3x5x35f4sb3wct2kx89w/North_America_26_transcript?position=7 French - https://cdn.bfldr.com/D6LGWP8S/as/jcbg3x5x35f4sb3wct2kx89w/North_America_26_transcript?position=3 Portuguese - https://cdn.bfldr.com/D6LGWP8S/as/jcbg3x5x35f4sb3wct2kx89w/North_America_26_transcript?position=6 Italian - https://cdn.bfldr.com/D6LGWP8S/as/jcbg3x5x35f4sb3wct2kx89w/North_America_26_transcript?position=5 German - https://cdn.bfldr.com/D6LGWP8S/as/jcbg3x5x35f4sb3wct2kx89w/North_America_26_transcript?position=4 Arabic - https://cdn.bfldr.com/D6LGWP8S/as/jcbg3x5x35f4sb3wct2kx89w/North_America_26_transcript?position=2 Please visit: www.openpediatrics.org OPENPediatrics™ is an interactive digital learning platform for healthcare clinicians sponsored by Boston Children's Hospital and in collaboration with the World Federation of Pediatric Intensive and Critical Care Societies. It is designed to promote the exchange of knowledge between healthcare providers around the world caring for critically ill children in all resource settings. The content includes internationally recognized experts teaching the full range of topics on the care of critically ill children. All content is peer-reviewed and open-access, thus at no expense to the user. For further information on how to enroll, please email: openpediatrics@childrens.harvard.edu Please note: OPENPediatrics does not support or control any related videos in the sidebar; these are placed by YouTube. We apologize for any inconvenience this may cause.

The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:1. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes Results From the VESALIUS-CV Trial. JAMA 2026. Discussion by:Guest:Jessica Stieritz, MDResident - Abington Family Medicine Residency Program Jefferson Health2. A treat-to-target strategy versus symptom-driven management of gout in the Netherlands (GO TEST Overture): a multicentre, open-label, pragmatic, superiority, randomized controlled trial. Lancet Rheumatology 2026. Discussion by:Guest:Neil Skolnik, MDProfessor of Family and Community MedicineSidney  Kimmel  Medical College Thomas Jefferson UniversityAssociate Director - Family Medicine Residency ProgramJefferson Health – Abington3. Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients. NEJM 2026 Discussion by: Guest:Steven Leonard, MD Resident - Abington Family Medicine Residency Program Jefferson HealthMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. This Podcast Episode does not offer CME/CE Credit. Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

Breast Cancer Briefing, hosted by Sara Nunnery, MD, MSCI, a breast medical oncologist and the director of Breast Cancer Research at Tennessee Oncology in Nashville, is a podcast series that breaks down the latest news in breast cancer research, one conversation at a time.In part 2 of this conversation, filmed live onsite at the 43rd Annual Miami Breast Cancer Conference, Dr Nunnery sat down with Neil M. Iyengar, MD, an associate professor and co-director of Breast Medical Oncology in the Department of Hematology and Medical Oncology at the Emory University School of Medicine, as well as the director of Survivorship Services at the Winship Cancer Institute of Emory University in Atlanta, Georgia.Their conversation highlighted the evolving integration of GLP-1 agonists into the breast cancer treatment armamentarium.

This mini-series on Behind the Knife delves into the technical aspects of the Operative Standards for Cancer Surgery, developed through the American College of Surgeons Cancer Research Program and Cancer Surgery Standards Program. This episode highlights sentinel lymph node biopsy for breast cancer.Hosts:- Lexy (Alexandra) Adams, MD, MPH (@lexyadams16) is a Surgical Oncology fellow at MD Anderson Cancer Center.- Lauren Postlewait, MD, FACS, is an Associate Professor of Surgery at Emory University School of Medicine and is the Medical Director of the Breast Center at Grady Memorial Hospital in Atlanta, GA.- Chantal Reyna, MD, FACS (@kprgrl3) is a Breast surgical oncologist at Loyola University Medical Center in Chicago, IL and serves as the oncology clinical lead for the breast service line.Guest:- Susan E. Pories, MD, FACS (@SusanPoriesMD) is a professor of surgery, vice chair for quality and safety, and director of the Rutger's Breast Center at the University hospital. Learning Objectives: -       Understand the definition and identification of axillary sentinel lymph node. -       Understand the technique for injecting tracer or dye to perform sentinel lymph node biopsy. -       Understand the importance of preincision drainage evaluation and transcutaneous localization.-       Understand techniques to minimize seroma formation.Links to Papers Referenced in this EpisodeOperative Standards for Cancer Surgery, Volume 1: Breast, Lung, Pancreas, Colonhttps://www.facs.org/quality-programs/cancer-programs/cancer-surgery-standards-program/operative-standards-for-cancer-surgery/purchase/Kindle edition:https://www.amazon.com/Operative-Standards-Cancer-Surgery-Section-ebook/dp/B07MWSNFSBSentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial Lancet Oncol. 2010 Oct;11(10):927-33.https://pubmed.ncbi.nlm.nih.gov/20863759/Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection J Clin Oncol. 2016 Apr 1;34(10):1072-8.https://pubmed.ncbi.nlm.nih.gov/26811528/The false-negative rate of sentinel node biopsy in patients with breast cancer: a meta-analysis World J Surg. 2012 Sep;36(9):2239-51. https://pubmed.ncbi.nlm.nih.gov/22569745/Effect of lymphoscintigraphy drainage patterns on sentinel lymph node biopsy in patients with breast cancer Am J Surg. 2005 Oct;190(4):557-62.https://pubmed.ncbi.nlm.nih.gov/16164919/Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial JAMA Oncol. 2023 Nov 1;9(11):1557-1564.https://pubmed.ncbi.nlm.nih.gov/37733364/Choosing Wisely GuidelinesSociety of Surgical Oncology. Released 2016 July 12; last updated 2020 November 13. Choosing Wisely: Five Things Physicians and Patients Should Question.https://surgonc.org/wp-content/uploads/2020/11/SSO-5things-List_2020-Updates-11-2020.pdfPlease visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium:General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewOral Board Simulator: https://app.behindtheknife.org/oral-board-simulatorTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Forty million people use ChatGPT for health-related questions every day, making it one of the most widely used tools for health information in the world. So what is their team doing to maximize impact and minimize harm? For one, they've brought in hundreds of physicians globally to continuously review outputs and shape how the models respond across different scenarios, literacy levels, and edge cases. Second, they've hired my Rock Health co-founder, Nate Gross, MD, as their VP of Health.In this full-circle episode, I sit down with Nate, who also co-founded Doximity (DOCS) and knows a thing or two about building in digital health. We discuss the astonishing speed of AI progress, how models are trained for safety and accuracy, and what this technological evolution means for every part of the healthcare system.Key topics:How ChatGPT is becoming a 24/7 front door for health questions, and whether it is replacing Dr. Google or starting to compete with the healthcare system itselfHow OpenAI is trying to reduce hallucinations, avoid sycophantic behavior, and build guardrails for sensitive use cases like mental healthOpenAI's goals to “raise the floor, sweep the floor, and raise the ceiling” with new product launches like ChatGPT for Clinicians and GPT-RosalindHow Nate thinks about the AI race and what winning in healthcare actually requiresWhere startups should focus their efforts now that specialized products are launching for clinicians and life sciencesThe single hardest problem in healthcare that AI, according to Nate, probably won't fix anytime soon— About our guest:Dr. Nate Gross is the VP of Health at OpenAI. He previously co-founded Doximity and Rock Health. He graduated from the Emory University School of Medicine with an MD, Harvard Business School with an MBA, and Claremont McKenna College with a BA in Government. He serves as affiliated faculty for the Clinical Informatics Fellowship at Stanford.— Show notes:ChatGPT for CliniciansChatGPT for Health (for patients)OpenAI for HealthcareGPT-Rosalind—

The "Community Meets Clinic" podcast series introduces clinicians and healthcare personnel specializing in rare neuroimmune disorders. In this episode hosted by Krissy Dilger of SRNA, we met Dr. Grace Gombolay and Dr. Varun Kannan, both from Emory University and Children's Healthcare of Atlanta, designated Centers of Excellence in Rare Neuroimmune Disorders. Dr. Kannan discussed learning alongside families as conditions like MOG antibody disease emerged clinically and his focus on tailoring treatment and supporting clinical trials in a field with few approved therapies [03:37]. Dr. Gombolay outlined her research on biomarker development, a Children's biobank, advanced MRI collaborations, and participation in the Network of Pediatric MS Centers covering disorders such as MOGAD, NMOSD, optic neuritis, ADEM, and TM [06:36]. They described their multidisciplinary clinic team, highlighted home infusions and telemedicine to reduce burden, and shared personal self-care strategies [10:22]. Dr. Gombolay and Dr. Kannan expressed hope for more trials, remyelination, prevention, and earlier diagnosis aided by AI prompts [20:43].You can view Dr. Grace Gombolay's medical profile here:https://www.choa.org/doctors/grace-gombolayYou can view Dr. Varun Kannan's medical profile here:https://www.choa.org/doctors/varun-kannanGrace Gombolay, MD, MSc, FAAN is an Associate Professor at Emory University and Director of the Pediatric Neuroimmunology and Multiple Sclerosis Clinic at Children's Healthcare of Atlanta. Her research interest involves biomarker development in pediatric neuroinflammatory diseases including autoimmune encephalitis, multiple sclerosis, MOGAD, and NMOSD.Varun Kannan, MD graduated from Emory University School of Medicine in 2017. He then completed child neurology residency in 2022, followed by pediatric neuroimmunology and multiple sclerosis fellowship at Baylor College of Medicine and Texas Children's Hospital in 2023. He returned to Emory and Children's Healthcare of Atlanta in 2023, where he has worked closely with Dr. Grace Gombolay in the neuroimmunology program. He is interested in clinical research regarding severe/relapsing forms of rare neuroimmune disorders including autoimmune encephalitis and MOGAD. He is currently involved in multiple upcoming phase 3 clinical trials exploring new disease modifying treatments for pediatric rare neuroimmune disorders. He is also passionate about medical education and is currently one of the Associate Program Directors for the Emory child neurology residency.00:00 Welcome01:56 Dr. Grace Gombolay's Journey03:37 Dr. Varun Kannan's Path05:06 Kannan's Research Focus06:36 Biomarkers and Biobank10:22 Clinic Team and Care13:44 Self Care and Balance16:15 Children's Healthcare of Atlanta20:43 Hopeful Future Ahead24:49 Closing

Many pediatricians care for underserved populations, and have long recognized the inextricable links between the well-being of families and the outcomes for their children.  Dr. Terri McFadden, professor of pediatrics at Emory University School of Medicine, medical director for Reach Out and Read Georgia, and president-elect for the American Academy of Pediatrics, joins us to talk about a new book which serves as a valuable 'how-to' on applying a two-generation approach to serving children and their families in an integrated manner — and offers primary care strategies for promoting optimal health and better developmental outcomes for children living in low-resourced environments.

Dr Matthew Milowsky from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, comments on real patient cases of metastatic urothelial bladder cancer presented by Dr Jacqueline T Brown from the Emory University School of Medicine in Atlanta, Georgia, and Dr Nazli Dizman from The University of Texas MD Anderson Cancer Center in Houston.CME information and select publications here.

In this episode we discuss with Rabbi Dr. Michael J. Broyde the evolution, especially in the past half century, of communal standards for tzniut in dress, particularly among women; whether laws of tzniut over the millennia have been objective and fixed, or subject within bounds to changing societal norms; possible U.S. societal changes that might affect tzniut in the Orthodox community; the positive benefits of increasing diversity in the Orthodox community, especially in the U.S.; Haredi shifting values relating to learning and working, Rabbi Broyde is a professor of law at Emory University School of Law and a leading scholar at the intersection of law, religion, and Jewish ethics. He is also Berman Projects Director and senior fellow at Emory's Center for the Study of Law and Religion, and teached Jewish Law at Columbia University. His most recent book, "Splitting Hairs," which we discuss in some detail, is a rigorously argued and refreshingly candid halakhic study of women's hair covering and tzniut more broadly. It is available at Amazon … click HERE. Ordained at Yeshiva University, he served for many years as a dayan on the Beth Din of America and was the founding rabbi of Young Israel of Toco Hills in Atlanta. He holds a JD from New York University School of Law and has authored hundreds of articles and numerous books on Jewish law, family law, bioethics, religious freedom, and comparative religious law. In recent years, he has written on such topics as religious arbitration, kidney transplants and vouchers, Jewish law and modesty, and a modern explication of the Book of Genesis. Rabbi Broyde can be reached at mbroyde@emory.edu, and he welcomes emails. A Times of Israel interview about his new book is available at this LINK.

With the launch of a new journal, the American Diabetes Association (ADA) is also launching a brand new podcast: The Points of CARE, the official podcast of Diabetes, Obesity, and CardioMetabolic CARE. Join hosts Richard Beaser, MD and Jane Reusch, MD, as they highlight key research findings, clinical implications, and emerging themes across diabetes, obesity, and cardiometabolic health through interviews with journal authors and subject-matter experts. 2:30 After introducing his co-host, Jane Reusch, Beaser speaks with James Gavin, MD, PhD, of the Emory University School of Medicine and Naunihal Virdi, MD, MBA, FACP, of Abbott Diabetes Care. They are the authors of "Advancing Type 2 Diabetes Care: The Role of Continuous Glucose Monitoring in Noninsulin-Treated Patients," available for free at doi.org/10.2337/doc25-0058. 13:00 Our hosts are joined by Ivy Shi, MD and Dhruv Kazi, MD, MSc, MS, both of Beth Israel Deaconess Medical Center. They are the authors of "GLP-1 RA Eligibility in Reproductive-Age U.S. Women," available in the March/April issue of Diabetes, Obesity, and CardioMetabolic CARE. 19:40 Next, Eva Tseng, MD, MPH, associate professor of medicine at Johns Hopkins School of Medicine joins the podcast. Her article, "START Diabetes Prevention: A Multilevel Strategy for Primary Care Clinics," is available in the March/April issue of Diabetes, Obesity, and CardioMetabolic CARE. To learn more about Diabetes, Obesity, and CardioMetabolic CARE please visit diabetesjournals.org/docm-care. Thank you for listening, and don't forget to subscribe.

Novel MRI biomarkers, including cortical lesions, the central vein sign, and paramagnetic rim lesions, are highly specific for MS and can aid diagnosis in select clinical scenarios, particularly early in the disease course or in atypical presentations. When used with appropriate MRI sequences, these markers can improve diagnostic sensitivity while helping prevent misdiagnosis. In this episode, Casey Albin, MD, speaks with Jiwon Oh, MD, PhD, FRCPC, FAAN, author of the article "Diagnostic Neuroimaging Biomarkers for Multiple Sclerosis" in the Continuum® April 2026 Multiple Sclerosis and Related Disorders issue. Dr. Albin is a Continuum® Audio interviewer, associate editor of media engagement, and an assistant professor of neurology and neurosurgery at Emory University School of Medicine in Atlanta, Georgia. Dr. Oh is the medical director of the Barlo Multiple Sclerosis Program at St. Michael's Hospital and an associate professor at the University of Toronto in Toronto, Ontario, Canada. Additional Resources Read the article: Diagnostic Neuroimaging Biomarkers for Multiple Sclerosis Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @caseyalbin Full episode transcript available here Dr Albin: Spend any time in a neurology conference, and you are certain to hear about the new central vein sign, which, as I learn, is not actually all that new. But have you heard about cortical lesions or these paramagnetic rim lesions? Because today I have the privilege of talking to Dr Jiwon Oh about her article, and we're going to unpack all these new biomarkers in MS. Dr Jones: This is Dr Lyell Jones, editor in chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Albin: Hello, this is Dr Casey Albin. Today I'm interviewing Dr Jiwon Oh about her article on diagnostic neuroimaging biomarkers for Multiple Sclerosis, which appears in the April 2026 Continuum issue on multiple sclerosis. Welcome to the podcast. Thank you so much for being here. I'd love to start by having you introduce yourself to our listeners.  Dr Oh: Thanks, Casey. Hi, everybody. My name is Jiwon Oh and I'm a neurologist, mainly an MS specialist at Saint Michael's Hospital at the University of Toronto, and I'm the medical director of our MS program. Dr Albin: And you have written a really fantastic article that dives deep into some of the nitty gritty about these new diagnostic biomarkers that we find on the MRI that we're getting for our patients with multiple sclerosis. And I think we are going to get into a lot of that nitty gritty. How do we look for them? How do they improve our diagnostic specificity? This is really come a long way in shaping the advances for multiple sclerosis. And I'd kind of like to just start with the big picture. Like why do we need these more specific biomarkers?  Dr Oh: This set of diagnostic criteria in MS, it's actually a huge change in the field, and particularly for people like me who are really interested in developing new MRI measures, we're really, really excited because it's actually the first time since MRI was officially incorporated into the MS Diagnostic criteria, which was way back in 2001. It's the first time that we've actually been able to get newer, more advanced imaging measures beyond just simply detecting, new T2 lesions in the MS diagnostic criteria. So, it's a big moment in the field, and many of us are really excited about it in terms of why we need some of these newer, more specific imaging measures. Well, you know, diagnostic criteria always evolve over time for any disease state, and MS is one that we've recognized over the years. By the time someone actually presents with typical clinical symptoms and has diagnosed, whatever has been happening from a patho-biological standpoint has been happening probably for almost 5 to 10 years before that individual actually presents. And so, because of this recognition in the field and the fact that we're recognizing how important it is to first diagnose MS and then treat MS earlier and earlier, because we know that early treatment helps prevent more clinical outcomes. Diagnostic criteria over time have become much more permissive, meaning that we're doing everything that we can to try to facilitate a diagnosis of MS when we know that someone biologically has MS. But the problem with making diagnostic criteria more permissive, and it's obviously a good thing because you want to capture as many people with MS as early on as possible. The problem with making it permissive is there is this terrible risk of misdiagnosis. As clinicians, we all think we never make mistakes. But it turns out when you actually do studies, you do. And even at MS specialty centers, when studies have been done, 10% to 20% of people with MS are misdiagnosed. So, this is exactly why we need in diagnostic criteria that really help to facilitate a diagnosis. We need things that help us prevent misdiagnosis as well. And these are these specific imaging measures that have now been incorporated into the diagnostic criteria in many settings that will help to facilitate a diagnosis. But the really big perk is if you use them, you can help to prevent misdiagnosis as well.  Dr Albin: Yeah, that really shone through in your article that this was such a big step in towards being more specific about who were diagnosing. Also capturing more people, right? Trying to get those people that we, we don't want to miss because of all the things you say, you know, that allows them to accumulate more disability, have worse outcomes. Early diagnosis is so important. But I really did take away from your article just how critical these are and sharping our diagnostic acumen. And so just to jump right in, and you describe these three new biomarkers, these cortical lesions the central vein sign and paramagnetic rim lesions. And so just to kick things off let's start with cortical lesions I sort of conceptualize multiple sclerosis a disease of white matter. So, what's going on here?  Dr Oh: Yes. MS classically has always been described as a white matter disease. But it turns out when you look at brain and spinal cord tissue, as well as when you use kind of better sequences to actually look for lesions in the gray matter, it actually turns out there's a ton of lesions in the gray matter as well. And in fact, what's interesting is that regardless of whether it's the cortex or the deep gray matter, it's lesions within these areas that seem to have the highest relevance for clinical disability in MS. So, all this to say, of course, MS is a lesion that does affect white matter, but it also affects gray matter a lot. And maybe pathology within the gray matter is even more relevant to clinical disability. So, this is why we're really interested in being able to develop methods using MRI to more accurately visualize the gray matter, particularly the cortex, as well as deep gray matter structures like the thalamus. I should add the caveat that cortical lesions were actually included in the 2017 diagnostic criteria revisions, but they were included together with juxtacortical lesions, which are a typical area that MS lesions form. And so, this imaging measure, despite the fact that it is relatively novel and we consider it advanced, it hasn't been used that much only because it's not that easy to detect lesions within the cortex. And reasons for this include that you usually need higher field magnet platforms. And so, the typical clinical MRI scanners that are available kind of widely, regardless of whether you're at an academic center or a community center, are 1.5 Tesla magnets. And cortical lesions are actually really difficult to detect on those typical scanners. But when you get to like, say, three Tesla or seven Tesla, they're a lot easier to detect. But obviously that's a big hindrance to widespread use. And then you actually need very specialized sequences to adequately visualize cortical lesions. And these are not sequences that are usually collected for clinical purposes. So, it kind of requires convincing your radiologists that you need this additional sequence. And then it actually takes a lot of time and training to be able to adequately, accurately detect cortical lesions. So, despite the fact that it's actually very useful when you do have the appropriate MRI sequences and scanners to detect cortical lesions, even though they were incorporated into the 2017 criteria outside of specialty centers, they're not actually widely used. But when you do have the appropriate sequences, cortical lesions are actually pretty specific for MS. So, very helpful for a diagnosis in certain settings. But there's all these practical limitations that have really limited its widespread use. Dr Albin: That is a beautiful summary. So, it sounds like once we kind of get up to speed in terms of like the protocols for this, having the magnet strength for this, this will be really a game changer in terms of increasing the specificity and also maybe finding things that impact patient's clinical presentation and therefore quite meaningful. But it sounds like for most of us, this is probably not something that they're going to be adopting right away. Is that a fair assessment?  Dr Oh: Yes. And you know, they were included in the last diagnostic criteria revisions. And it really hasn't changed things very much, only because of these difficulties with, you know, requiring higher field magnet strengths and these specialized sequences and then needing training to kind of figure out how you can adequately detect cortical lesions. Dr Albin: Totally. So, the other thing we've heard a lot about, and I have to say, I was in the AAN fall conference not too long ago, and this came up quite a bit, was the central vein sign and the fascination with that, because it tells us a lot about the MS pathophysiology and again, increasing that specificity. And it seems like maybe this is one that we can more easily adopt in clinical practice. So, tell our listeners about what that is, how they detect it. How many do you need to find?  Dr Oh: Sure. And so, this is one of the imaging measures I'm really excited about. So, the central vein sign heard about it recently. And probably in the last ten years particularly in the MS field we're talking about it all the time. But just wanted to emphasize that the central vein sign is not something that is new. Even back in the 1800s, when Charcot described MS lesions in these ancient textbooks, he actually very clearly described that MS lesions form around the central vein. And that makes sense, because we know that these waves of peripherally mediated inflammation somehow get through the blood-brain barrier and cause this cascade of events leading to inflammation in the brain and spinal cord, which is what MS is. But we know that B cells in T cells require veins to get into the central nervous system. And so, it's no surprise, really, that MS lesions form around veins. And so, this is something that's been known pathologically. But the reason we're so excited about it now is because we actually have good enough iron-sensitive MRI sequences that allow us to see a central vein when it is present within a white matter lesion. As a neurologist, we know that there's probably hundreds and hundreds of different things that can cause white matter lesions in the brain. But when you use an appropriate iron-sensitive sequence and you see that many of them, if not most of them, actually have visible central veins, that tells you that this person very likely has MS. And so that's why we're so excited about it, because there have been many studies done in the last ten years. In fact, so much evidence generated in the last ten years that there have been I think it's now four systematic reviews and meta analyzes. Looking at the diagnostic properties of the central vein sign. And, you know, it turns out that when you look at people with MS, most of them have a pretty high proportion of white matter lesions that have visible central veins. And there's a lot of questions about, you know, how to best use the central vein sign. But when 40% or more of the white matter lesions that you see have visible central veins, then the likelihood of a diagnosis of MS is very high. So, this is why we're so excited about it in the MS field because it's a really useful diagnostic tool. You know, again when you have appropriate ion sensitive sequences, if you see someone with white matter lesions and you see that 40% or more of them have visible central veins, this tells you that this person very likely has MS.  Dr Albin: So, Dr Oh, I hear you say, you know, 40% of the lesions. Does that mean the neuro radiologist needs to look at every single lesion and then count how many have the central veins, or is there an easier way to do this? Dr Oh: Great question. Casey, there is definitely an easier way because our neuro radiologists would not be our friends anymore if we made them look at every white matter lesion and make sure that 40% of them had the central vein sign. So, because it's so time-consuming to use that 40% threshold, there's an easier criterion that has actually made it into the diagnostic criteria. And it's called Select Six. And what this means is when you have more than ten lesions, as long as you show that six of them have a visible central vein, you just have to count six with the central vein. Then you're done. So that means you're Select Six positive or central veins nine positive. However, if you have ten or fewer lesions, as long as you show that more than 50% of them show a visible central vein, then you are select six positive, and then you're done. So, as you can see, it's a much simpler criterion to apply, and it seems to perform almost as well as that 40% threshold, which is why that is the criterion that's made it into the new diagnostic criteria.  Dr Albin: Perfect. I love that we definitely do not want to make enemies with our neuro radiology colleagues, but yet they do so much for us. So perfect. I'm glad that we can, make their jobs a little easier without losing any specificity there, or just losing a touch of specificity there. All right. If I am working with a, you know, in a center that maybe doesn't do this all the time, am I just getting a run of the mill SWI sequence? Do I need to ask my radiologist for a special sequence? Or is this just, you know, you can get it from the typical array of what our patients are getting.  Dr Oh: You know, SWI is a widely available commercial sequence that's iron-sensitive, the ones that are typically commercially available, they can detect central veins, but there actually are little tweaks that you can do to make it a little more optimal. With the recent diagnostic criteria publication, which was, led by Xavier Montalban and recently published in Lancet Neurology. There's actually a companion MRI paper that was led by Frederick Barkov and Danny Wright. And the reason I'm specifically citing those papers is in that companion MRI paper, there's a table that has kind of optimal sequence parameters that you can use even with a conventional SWI sequence, to try to best detect the central vein sign. And then there's a wide range of different iron-sensitive sequences, and SWI is one of them, but the one that seems to have emerged as most sensitive to detect the central vein sign is something called the 3D T2*-EPI sequence. But the bottom line is there's a whole bunch of different iron-sensitive sequences that you can use, little tweaks that you can do to make them optimal, to be able to visualize central veins when they're present within white matter lesions. Dr Albin: Incredible. So like partner with your neuro radiologist, there is a great sounds like a field guide almost to this. So, it makes it easy to pick up in your standard of care so that you can make sure that you are detecting them at the optimal level to see that more specific diagnostic biomarker.  Dr Oh: Yes. And you know, in contrast to what we were talking about with cortical lesions, you can actually detect central veins when you use these iron-sensitive sequences at any field magnet. So even at 1.5 Tesla, particularly when you use contrast, which is often given with the diagnostic scan anyway, you can very easily detect a central vein. So that's a huge benefit because it allows for widespread use. As long as you work with your radiologist to get the right iron-sensitive sequences in.  Dr Albin: Yeah, that's incredible. I mean, I think that it really will be practice-changing. And then the last one that I think was honestly new to me, I feel like I had heard a lot about the central vein sign, but the whole new to me term was this paramagnetic rim lesion. So, what does that tell us about the underlying biology of MS? And are there any other things that might also have this finding that we should sort of be aware of? And how specific is it?  Dr Oh: You know, the central vein sign is kind of the main, really new imaging measure that's made it into every part of the MS diagnostic criteria. And then together with that paramagnetic rim lesions or we call them PRL or pearls for short, they've made it as well, but in a much more limited way only because there's not as much evidence that has accumulated over time to support the diagnostic utility of pearls. But first of all, what are pearls? So, people in the MS field are really excited about pearls, because we know that they capture a subset of what we call chronic active lesions. So, MS lesions will form acutely and over time, some of them will become inactive. And then some of them are chronic active lesions, meaning that they have this rim of activated microglia around them. Over time, they continue to slowly expand. And it's almost like this slow burn. And the reason why we focus a lot on chronic active lesions is because we know that they're a driver of progressive disease biology and MS, meaning that in people who have progressive MS or who have pretty severe disability, global disability or cognitive disability, we know that they have a high burden of pearls. And so that's why there's so much excitement in MS about being able to image chronic active lesions. It's because we're always looking for an imaging measure that allows us to accurately predict progression or to, measure progression over time. So that's why there's so much excitement in MS about pearls. But as kind of an added bonus, it turns out pearls are also really specific for MS. And so, when you use the same iron-sensitive sequences, by the way, that's used to detect the central vein sign when you use appropriate iron‑sensitive sequence. And if you see that someone has a pearl, the likelihood of a diagnosis of MS is very high. The one exception to that is Susac syndrome, where pearls have been observed. But other than that, with many other white matter diseases like neuro rheumatology disease, NMOSD, MOGAD, you really don't see pearls. And so, this is why it's made it into the new diagnostic criteria. In contrast to the central vein sign, though, not everybody with MS has a pearl, so the sensitivity isn't as high. However, it's really, really specific in the range of, you know, 90 to 95%. So, this is why it's been added as, an imaging measure in certain settings. It can help facilitate a diagnosis. But the real utility, again, is when you use it, it helps you to prevent misdiagnosis.  Dr Albin: It's fantastic. And hearing you talk about that, this one stands out to me as a biomarker that not only helps increase our diagnostic specificity, but also may really inform if the patient has having progression despite the treatment they're on, that this could play a role in helping you say, look, there probably is something that we need to switch because we can still see this ongoing progression. Dr Oh: Yes. And especially in this new era of treatment in MS. I think, you know, MS as a field, we've been so fortunate to have so many treatments emerge over the years that mainly target relapsing disease. But we hopefully, in the next little while, in short order, I hope we'll have treatments that target these progressive disease biologies. And so, not only is it helpful as a diagnostic marker, but there's a lot of evidence accumulating, showing that it may have a lot of prognostic value and will also help guide treatment decisions, exactly as you said.  Dr Albin: It truly does sound like it's a great time to be an MS doctor there. So, so many new advances in the field. There is so much more that we can do for these patients in our limited time left. I'd love to ask you, what is it that you're most excited about now with the change in the biomarkers, the change in the treatment, what makes you really excited to be a doctor specializing in MS right now? Dr Oh: I feel like we're on the brink of a new era of treatment. I think, you know, in the last two decades, MS care has changed so dramatically. I remember, you know, way back when, as a medical student, when I did my first neurology elective, this was when the first treatments for MS were emerging. And the prognosis that we were talking to patients about at that time is like night and day compared to what we talk to them about now. But we're going to do even better in the next couple of years. And so, there's a number of new treatments that hopefully will be approved soon that, for the first time, have shown an effect in clinical trials where it seems to be decreasing progression that is independent of relapsing activity. And that's really the greatest unmet treatment need that we have. And it seems like we might have some therapies on the horizon that can actually target that aspect of progression. It's really exciting, and even more that we're going to be able to do for our patients to completely change the way, we look at and the way we treat MS in the years to come.  Dr Albin: Dr Oh, this has just been fantastic. To all of our listeners, I really want to point you to the article because obviously, as an imaging biomarker article, there are so many beautiful images. There are great examples. There are some fantastic cases that show how applying these new biomarkers can help get you to the right diagnosis. This is truly a tour de force of how imaging has really shifted the care that we provide patients with MS, and so please go and check it out. It is one that you do not want to miss. And again, today I've been interviewing Dr Jiwon Oh about her article on diagnostic neuroimaging biomarkers for multiple sclerosis, which appears in the April 2026 Continuum issue on multiple sclerosis. Thank you again, Dr Oh, this has just been such a delight.  Dr Oh: Thank you for having me on the show, Casey, and look forward to people reading the article. Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

Being on the caregiver side of complex, rare disease care reveals critical gaps in our healthcare system, even for two physician parents with strong connections. In this powerful follow-up episode of Succeed In Medicine, host Dr. Bradley Block welcomes back Dr. Heather Gatcombe, as she recounts her family's journey: her son's initial metabolic stroke-like episodes at age 7, the five-year path to a definitive mitochondrial disease diagnosis (including a muscle biopsy and eventual identification of a pathogenic variant), sudden heart failure at age 11 during the COVID-19 pandemic, ECMO, LVAD placement, and successful heart transplant. She openly discusses the immense challenges of hospital discharge with an LVAD when no pediatric rehab would accept him, managing tube feeds and alarms at home without adequate home health support, and the frustration of subtle symptoms like throat clearing being overlooked as a sign of heart failure. Dr. Gatcombe also reflects on moments where she felt her family wasn't fully heard, and the lasting impact of those experiences. Throughout the conversation, she shares how this journey has made her a more empathetic and effective clinician, particularly in communicating uncertainty, avoiding premature reassurance, listening to parental intuition, ensuring robust discharge planning with support services, and staying curious even when a diagnosis remains elusive. This episode offers practical lessons for all physicians on improving communication, supporting families through diagnostic uncertainty, preparing patients for safe transitions home, and the power of transparency and advocacy in rare disease care. Three Actionable Takeaways: Communicate uncertainty honestly and compassionately: When the diagnosis isn't clear yet, be transparent about what you know and don't know. Offer guidance on next steps, second opinions, and support resources rather than premature reassurance that may later need to be walked back. Prioritize discharge planning and support services: The transition from hospital to home is one of the most vulnerable periods. Ensure patients and families have home health, equipment (wheelchair, shower chair, etc.), dietician and nurse navigator follow-up, and clear instructions before discharge, especially for medically complex cases. Listen to patients and families as the experts on their own bodies: Parental intuition and lived experience matter. When a child or family member expresses concern, even if it seems outside the norm,  take it seriously, investigate, and avoid dismissing it. Follow up after adverse events when possible to maintain trust. About the Show: Succeed In Medicine covers patient interactions, burnout, career growth, personal finance, and more. If you're tired of dull medical lectures, tune in for real-world lessons we should have learned in med school! About the Guest: Dr. Heather Gatcombe is a board-certified radiation oncologist at Winship Cancer Institute of Emory University and an Assistant Professor at Emory University School of Medicine. She specializes in breast radiation oncology and serves as Vice Chair for Community and Belonging. As the mother of a child with mitochondrial disease who experienced metabolic strokes starting at age 7, progressing to heart failure and transplant, she is deeply committed to raising clinician awareness, reducing diagnostic delays, and advocating for patients and families. She serves on the Board of Trustees and the Scientific and Medical Advisory Board Clinical Training and Education Committee of the United Mitochondrial Disease Foundation (UMDF). Website: https://winshipcancer.emory.edu/profiles/gatcombe-heather.php LinkedIn: https://www.linkedin.com/in/heather-gatcombe-md-3891875 Instagram: https://www.instagram.com/heathergatcombe UMDF: https://umdf.org/about/board-trustees About the Host: Dr. Bradley Block – Dr. Bradley Block is a board-certified otolaryngologist at ENT and Allergy Associates in Garden City, NY. He specializes in adult and pediatric ENT, with interests in sinusitis and obstructive sleep apnea. Dr. Block also hosts Succeed In Medicine podcast, focusing on personal and professional development for physicians Want to be a guest? Email Brad at brad@physiciansguidetodoctoring.com  or visit www.physiciansguidetodoctoring.com to learn more! Socials: @physiciansguidetodoctoring on Facebook @physicianguidetodoctoring on YouTube @physiciansguide on Instagram and Twitter This medical podcast is your physician mentor to fill the gaps in your medical education. We cover physician soft skills, charting, interpersonal skills, doctor finance, doctor mental health, medical decisions, physician parenting, physician executive skills, navigating your doctor career, and medical professional development. This is critical CME for physicians, but without the credits (yet). A proud founding member of the Doctor Podcast Network!Visit www.physiciansguidetodoctoring.com to connect, dive deeper, and keep the conversation going. Let's grow! Disclaimer:This podcast is for informational purposes only and is not a substitute for professional medical, financial, or legal advice. Always consult a qualified professional for personalized guidance. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this special edition on Continuous Ketone Monitoring our host, Dr. Neil Skolnik will discuss this new technology – its promise and its application. This special episode is supported by an independent educational grant from Abbott. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Guillermo Umpierrez, M.D.,  Professor of Medicine, Division of Endocrinology, Clinical Director of the Diabetes and Metabolism Center at Emory University School of Medicine, Director of the Diabetes and Endocrinology Section and Clinical Research Unit at Grady Memorial Hospital, Atlanta, Georgia. Member of the ADA Professional Practice Recommendation Committee, and Chair of the ADA Consensus Report on Hyperglycemic Crises in Adults with Diabetes.   Reference: Hyperglycemic Crises in Adults With Diabetes: A Consensus Report. Diabetes Care 2024;47:1257–1275 | https://doi.org/10.2337/dci24-0032

Breast Cancer Briefing, hosted by Sara Nunnery, MD, MSCI, a breast medical oncologist and the director of Breast Cancer Research at Tennessee Oncology in Nashville, is a podcast series that breaks down the latest news in breast cancer research, one conversation at a time.In today's episode, filmed live onsite at the 43rd Annual Miami Breast Cancer Conference, Dr Nunnery sat down with Neil M. Iyengar, MD, an associate professor and co-director of Breast Medical Oncology in the Department of Hematology and Medical Oncology at the Emory University School of Medicine, as well as the director of Survivorship Services at the Winship Cancer Institute of Emory University in Atlanta, Georgia.Their conversation centered around lifestyle and medical interventions pertinent to breast cancer survivorship. Dr Iyengar explained that although endocrine therapies can be life-saving, they disrupt estrogen signaling, which can lead to cardiometabolic dysfunction, including increased risks for diabetes, heart disease, and bone health issues. He noted that weight gain associated with these treatments is often tied to the induction of a post-menopausal state, which disrupts energy homeostasis and promotes inflammation.A key theme of the conversation was Dr Iyengar's explanation of a "drug development paradigm" for lifestyle changes. Rather than offering generic advice, his research focuses on precision lifestyle interventions, treating diet and exercise as prescribed medical therapies with specific "doses". He highlighted that body mass index (BMI) is an insufficient tool for risk stratification, as high body fat despite a normal BMI is a significant risk factor for cancer recurrence.The discussion also covered the rising use of GLP-1 receptor agonists to manage metabolic health. These drugs replicate natural hormones to maintain glycemic balance and reduce hunger. Dr Iyengar addressed the black box warning for thyroid cancer associated with this class of drugs, noting that although the data are mixed, the protective benefits against obesity-related cancers appear to outweigh the risks. Finally, he emphasized that exercise is a critical tool for managing treatment adverse effects like fatigue, noting that although starting is difficult, the "return on investment" for patient health is immense.

In episode 73 of Going anti-Viral, we represent a panel discussion from March 26, 2026, as part of the IAS–USA Dialogue series Emerging Infections and Health Threats. This Dialogue is a must listen as our distinguished panel of infectious disease experts dives deep into some of the most pressing public health challenges facing the world today. Moderated by Carlos del Rio, MD, a Distinguished Professor of Medicine in the Division of Infectious Diseases at Emory University School of Medicine, this Dialogue brings together world-class experts Yvonne Maldonado, MD, and Peter Chin-Hong, MD. The panel discusses a recent federal court ruling regarding the Advisory Committee on Immunization Practices (ACIP) and addresses the latest news on rates of vaccination and an update on emerging viral outbreaks, including measles, influenza, COVID-19, meningitis, tuberculosis, mpox, and RSV. The panel also reflects on the implications of the lack of leadership at the CDC on public health.0:00 – Introduction 2:33 – March 2026 federal court ruling pausing the work of the ACIP7:08 – Review of the reduction in immunization rates in the US12:51 – Measles cases in the US and efforts to address misinformation20:28 – Breaking down recent influenza rates 25:42 – Update on COVID-19 – variants and vaccination33:42 – Leadership gap at the CDC and implications for public health 41:35 – Meningitis outbreak in England and status of vaccination in the US49:46 – Increase in cases of tuberculosis in the US56:45 – Update on mpox cases and vaccination59:12 – Brief review of RSV cases and vaccination and closing remarks __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:1. Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study. BMJ 2026. Discussion by:Guest:Susan Kucher, MDProgram Director - Abington Family Medicine Residency Program Jefferson Health2. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes Results From the VESALIUS-CV Trial. JAMA. Discussion by:Guest:Neil Skolnik, MDProfessor of Family and Community MedicineSidney  Kimmel  Medical College Thomas Jefferson UniversityAssociate Director - Family Medicine Residency ProgramJefferson Health – Abington3. Prevalence of Youth Overweight, Obesity, and Severe Obesity. JAMA Network Open. Discussion by:  Guest:Neil Skolnik, MDProfessor of Family and Community MedicineSidney  Kimmel  Medical College Thomas Jefferson UniversityAssociate Director - Family Medicine Residency ProgramJefferson Health – Abington4. A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. New England Journal of Medicine 2026. Discussion by:Guest:Griffin Johnson, MDResident - Abington Family Medicine Residency Program Jefferson HealthMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. This Podcast Episode does not offer CME/CE Credit. Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

In today's episode, we spoke with Ticiana Leal, MD, about variability in community practice and evolving treatment strategies for patients with small cell lung cancer (SCLC). Dr Leal is a professor and director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine, as well as the medical director of the Clinical Trials Office at Winship Cancer Institute in Atlanta, Georgia.In our exclusive interview, Dr Leal began by discussing how SCLC management can differ widely across community settings according to how patients present. Leal emphasized the importance of quickly confirming a patient's diagnosis and initiating treatment to avoid missing the critical window where chemotherapy could provide meaningful clinical benefit. However, Leal noted that the field still lacks predictive biomarkers to guide treatment selection. Accordingly, current strategies, including chemoimmunotherapy, maintenance approaches, and second-line options like tarlatamab-dlle (Imdelltra) and lurbinectedin (Zepzelca) are largely chosen based on clinical factors such as disease burden, comorbidities, and patient preferences.The conversation then shifted to the challenge of treating patients who may not meet traditional clinical trial eligibility criteria due to poor performance status, comorbidities, or social vulnerabilities. Leal stated that a multidisciplinary approach, including collaboration with supportive care teams, is essential to optimize outcomes for these patients. She noted that potential solutions to restrictive trial eligibility criteria may include decentralizing trials, improving collaboration between academic and community centers, and providing additional patient support such as transportation and care navigation services.Looking ahead, Leal emphasized the need for community practices to prepare for emerging therapies, including antibody-drug conjugates and novel immunotherapy approaches. Successfully integrating these treatments into everyday practice will require education, infrastructure development, and multidisciplinary collaboration, Leal imparted.

In this episode of The ICHE Podcast, host Dr. David Calfee speaks with Jose Navarrete, MD. of Emory University School of Medicine and Marin Schweizer, PhD. of the University of Wisconsin about infection risks among patients receiving hemodialysis, including common pathogens and factors that increase vulnerability. They discuss their recent research and share key findings, along with practical insights on how to improve infection prevention in hemodialysis settings. https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/trends-of-bloodstream-infection-incidence-rates-among-patients-on-outpatient-hemodialysis-national-healthcare-safety-network-20122021/3DC9CCED04161F16F274F12919DC3F7C https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/abs/survey-of-hemodialysis-patients-knowledge-of-their-infection-risk-and-acceptability-of-an-intranasal-decolonization-intervention/EA68F7DAB1D54174D633E1DE5EE38136

Dr Matthew Milowsky from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, comments on real patient cases of metastatic urothelial bladder cancer presented by Dr Jacqueline T Brown from the Emory University School of Medicine in Atlanta, Georgia and Dr Nazli Dizman from The University of Texas MD Anderson Cancer Center in Houston. CME information and select publications here.

In this episode of The Visible Voices Podcast, Dr. Sharon Bergquist — physician, author of the Plantology cookbook, host of The Whole Health Cure podcast, and lifestyle medicine expert at Emory University School of Medicine — joins for an episode on food as medicine and chronobiology. Dr. Bergquist unpacks the science of when we eat, not just what we eat, explaining how meal timing shapes our circadian biology, metabolic health, and disease risk; she makes the case for front-loading calories earlier in the day, and rethinking "healthy" foods like farmed salmon, avocado, and eggs with more nuance. The conversation covers soil quality and dietary diversity, the gut microbiome, protein needs across the lifespan, the community and mindfulness dimensions of eating, and practical take-homes for anyone looking to leverage food as one of our most powerful tools for prevention and longevity. Follow Dr. Bergquist on Instagram at @drsharonbergquist and drsharonbergquist.com Wish to help the show? Leave ⭐⭐⭐⭐⭐ on Apple. Subscribe here and send it to a friend.

What if a patient's multisystem symptoms, unexplained strokes, or exercise intolerance point to mitochondrial disease, but it takes 5–10 years and multiple specialists to confirm? In this eye-opening episode, Dr. Bradley Block speaks with Dr. Heather Gatcombe. As both a physician and the mother of a son with mitochondrial disease, leading to metabolic strokes, heart failure, and transplant,  Dr. Gatcombe shares her family's journey, from a terrifying stroke-like episode at age 7, through years of uncertainty, negative initial genetic testing, muscle biopsy confirmation, and eventual identification of a novel nuclear DNA mutation. They explore the heterogeneity of primary mitochondrial diseases, why presentation ranges from infancy lethality to adult-onset fatigue, and key red flags: multisystem involvement, symptom worsening with metabolic stressors, and misdiagnoses like chronic fatigue syndrome, fibromyalgia, or psychiatric conditions. The discussion covers workup, multidisciplinary care, perioperative risks, and treatment.  They stress the power of early diagnosis: better empathy, treatment changes, support groups, and hope with new therapies in the pipeline. Clinicians in every specialty need awareness, especially anesthesiologists, surgeons, and hospitalists, to prevent crises. Three Actionable Takeaways: Spot the Warning Signs Early: Look for patients with symptoms in 3 or more organ systems, unexplained strokes or seizures, diabetes and hearing loss, brain lesions in basal ganglia, or symptoms that worsen with stress like fever, fasting, or surgery. Send them quickly to a geneticist or mitochondrial specialist for testing. Free options exist at umdf.org Protect Patients During Surgery or Procedures: For anyone known to have mitochondrial disease, talk to their mitochondrial specialist first. Avoid long fasting, dehydration, or extreme temperatures. Some need IV glucose before procedures and special care with anesthesia or certain drugs to prevent a dangerous metabolic crisis. Learn More and Speed Up Diagnosis: Visit umdf.org for free doctor education (CME courses), patient support groups, and the latest on new treatments. Raising awareness helps cut the long wait for diagnosis, gives patients validation, better care, and access to emerging FDA-approved therapies.  About the Show: Succeed In Medicine covers patient interactions, burnout, career growth, personal finance, and more. If you're tired of dull medical lectures, tune in for real-world lessons we should have learned in med school! About the Guest: Dr. Heather Gatcombe is a board-certified radiation oncologist at Winship Cancer Institute of Emory University and an Assistant Professor at Emory University School of Medicine. She specializes in breast radiation oncology and serves as Vice Chair for Community and Belonging. As the mother of a child with mitochondrial disease who experienced metabolic strokes starting at age 7, progressing to heart failure and transplant, she is deeply committed to raising clinician awareness, reducing diagnostic delays, and advocating for patients and families. She serves on the Board of Trustees and the Scientific and Medical Advisory Board Clinical Training and Education Committee of the United Mitochondrial Disease Foundation (UMDF). Website: https://winshipcancer.emory.edu/profiles/gatcombe-heather.php LinkedIn: https://www.linkedin.com/in/heather-gatcombe-md-3891875 Instagram: https://www.instagram.com/heathergatcombe UMDF: https://umdf.org/about/board-trustees About the Host: Dr. Bradley Block – Dr. Bradley Block is a board-certified otolaryngologist at ENT and Allergy Associates in Garden City, NY. He specializes in adult and pediatric ENT, with interests in sinusitis and obstructive sleep apnea. Dr. Block also hosts Succeed In Medicine podcast, focusing on personal and professional development for physicians Want to be a guest? Email Brad at brad@physiciansguidetodoctoring.com  or visit www.physiciansguidetodoctoring.com to learn more! Socials: @physiciansguidetodoctoring on Facebook @physicianguidetodoctoring on YouTube @physiciansguide on Instagram and Twitter   This medical podcast is your physician mentor to fill the gaps in your medical education. We cover physician soft skills, charting, interpersonal skills, doctor finance, doctor mental health, medical decisions, physician parenting, physician executive skills, navigating your doctor career, and medical professional development. This is critical CME for physicians, but without the credits (yet). A proud founding member of the Doctor Podcast Network!Visit www.physiciansguidetodoctoring.com to connect, dive deeper, and keep the conversation going. Let's grow! Disclaimer:This podcast is for informational purposes only and is not a substitute for professional medical, financial, or legal advice. Always consult a qualified professional for personalized guidance. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In today's episode, we spoke with Colin Vale, MD. Dr Vale is an assistant professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine in Atlanta, Georgia.In our exclusive interview, Dr Vale discussed data from a phase 2 trial (NCT03263572) evaluating blinatumomab (Blincyto) plus ponatinib (Iclusig) in patients with Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia. In addition to underscoring the findings and their clinical significance, Vale expanded on how the combination can improve patient quality of life by helping patients avoid procedures like allogeneic stem cell transplant.

In this episode, Dr. Andy Cutler talks with Dr. Robert Cotes about optimizing outcomes in early psychosis and why the first episode is a critical window for intervention. They discuss the impact of duration of untreated psychosis, recovery trajectories after a first episode, and what to measure beyond symptom reduction—including functional outcomes, cognition, and relapse risk. The conversation also highlights strategies for engaging young adults and families in coordinated specialty care, early identification of clinical high risk for psychosis, and innovations aimed at improving long-term recovery.  Robert O. Cotes, MD, is Professor of Psychiatry and Behavioral Sciences at Emory University School of Medicine and Chief of Psychiatry at Grady Health System in Atlanta. He directs the Clinical and Research Program for Psychosis at Grady, which includes Project ARROW, a coordinated specialty care program for young people with early psychosis, and a specialized clozapine clinic for treatment-resistant schizophrenia.    Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Save $100 on registration for 2026 NEI Spring Congress with code NEIPOD26  Register today at nei.global/spring  Never miss an episode!

In a conversation with CancerNetwork®, Sagar Lonial, MD, FACP, FASCO, discussed the potential implications of the FDA approving iberdomide plus daratumumab (Darzalex) and dexamethasone for patients with relapsed/refractory multiple myeloma. He spoke in context of the FDA accepting a new drug application for the iberdomide regimen based on data from the phase 3 EXCALIBER-RRMM trial (NCT04975997).Lonial discussed the potential benefits that iberdomide could offer based on its properties as a CELMoD. He noted how the potency, safety profile, and targeting capabilities of this drug class may differentiate it from previous standards such as immunomodulatory drugs.Regarding the supporting findings from the EXCALIBER-RRMM trial, Lonial stated that the study was the “first test case” for using minimal residual disease (MRD) as an early end point for approval. In September 2025, investigators announced that iberdomide-based therapy showed a significant improvement in MRD-negative status vs daratumumab, bortezomib (Velcade), and dexamethasone.The potential approval of iberdomide in this multiple myeloma population, Lonial said, would open the door for using the agent in combination with other immunotherapies. Noting that T-cell engagers are “perfect partners” for the CELMoD class, Lonial emphasized the utility of combination regimens across the field.“Recognizing that we have agents that can reset or augment immunity and partnering them [are important]. People always want to say it's a black and white world; you're either going to use this, or you're going to use this. To me, it's about combination therapy,” Lonial stated. “Having this tool belt with many drugs and putting them together in combinations is how we get to [a] cure.”Lonial is a professor and chair of the Department of Hematology and Medical Oncology and the Anne and Bernard Gray Family Chair in Cancer at Emory University School of Medicine, and the chief medical officer at Winship Cancer Institute of Emory University. He is also a member of the International Myeloma Foundation scientific board.References U.S. Food and Drug Administration accepts Bristol Myers Squibb's new drug application for iberdomide in patients with relapsed or refractory multiple myeloma. News release. Bristol Myers Squibb. February 17, 2026. Accessed March 5, 2026. https://tinyurl.com/4c8mb6ex Bristol Myers Squibb announces phase 3 EXCALIBER-RRMM study evaluating iberdomide in combination with standard therapies demonstrated a significant improvement in minimal residual disease negativity rates in relapsed or refractory multiple myeloma. News release. Bristol Myers Squibb. September 23, 2025. Accessed March 5, 2026. https://tinyurl.com/5n9768k5

Welcome to Transmission Interrupted! In this episode, host Jill Morgan sits down with the principal investigators of NETEC—Dr. Aneesh Mehta, Dr. Vikramjit Mukherjee, and Dr. John Lowe—to reflect on a decade of advancing special pathogen preparedness across the U.S. healthcare system. Together, they revisit the origins of NETEC, tracing back to the transformative events of the 2014 Ebola outbreak, and share their unique journeys as infectious disease experts, critical care clinicians, and scientists on the front lines. The conversation dives into the challenges and lessons learned while building a national network equipped for high-consequence infectious diseases, the evolution from isolated specialty units to a system-wide approach, and the critical importance of healthcare worker safety. You'll hear insights on what it takes to maintain readiness in a landscape of ever-changing threats, the value of interdisciplinary collaboration, and a call to expand this “tight-knit club” of preparedness champions. Whether you're a healthcare professional, public health advocate, or just curious about how the U.S. prepares for medical crises, this episode delivers an inspiring look at the past, present, and future of special pathogen response—and why it matters to us all. Guests John-Martin Lowe, PhD John-Martin Lowe, PhD, is the director of the Global Center for Health Security, assistant vice chancellor for health security training and education, and professor of Environmental, Agricultural and Occupational Health at the University of Nebraska Medical Center. At the University of Nebraska Medical Center, he leads research and training initiatives to advance environmental risk assessment and infection control for high consequence pathogens. As a virologist and environmental exposure scientist, Dr. Lowe has worked extensively throughout the U.S., Africa, Asia and Europe as an educator, researcher, and in health emergency risk management related to infectious disease, infection control and emergency response. As a professor of environmental and occupational health, his expertise focuses on infectious disease risk assessment and management of risk for clinical, community and industrial environments. Dr. Lowe also has extensive experience in emerging pathogens and health security. He is co-PI for the U.S. National Emerging Special Pathogens Training and Education Center, established an international network for emerging infectious diseases, and served lead investigator for a multi-country bio-surveillance network in Africa. He has experience in a broad range of health security topics from surveillance, public health response and clinical response to health emergencies. Dr. Lowe led successful COVID-19 efforts in 2020 at the National Quarantine Unit and Nebraska Biocontainment Unit to provide monitoring and care for repatriated U.S. citizens exposed to and infected with SARS Coronavirus 2. He also led early and continued efforts to characterize the transmission dynamics of SARS Coronavirus 2 which were presented to in a joint meeting hosted by the Academy of Medicine and American Public Health Association on April 15, 2020. Dr. Aneesh Mehta, MD, FIDSA, FAST Aneesh Mehta is a Professor of Medicine and of Surgery at Emory University School of Medicine, and also serves as the Chief of Infectious Diseases Services and Assistant Director of Transplant Infectious Diseases at Emory University Hospital. He is a board-certified infectious diseases physician, who received an MD from the University of Oklahoma and completed Internal Medicine and Infectious Diseases training at Emory University. Aneesh has been one of the core physicians of the Emory Serious Communicable Diseases Unit (SCDU) since 2009. He was admitted physician for Emory's first patient with Ebola Virus Disease and was highly involved in care of the four patients with EVD, one patient with Lassa Fever, and several PUIs cared for by the Emory SCDU. During the Ebola activation, Aneesh was involved in all aspects of unit management, patient care, laboratory handling, and research. Aneesh is a co-Principal Investigator at NETEC. He also has been involved in development of the Special Pathogens Research Network Biorepository and evaluation of Medical Countermeasures. Vikramjit Mukherjee, MD, FRCP (Edin) Vikramjit Mukherjee is an intensive care physician who serves as the Chief of Critical Care at NYC Health+Hospitals/Bellevue. He also is the Chief of Bellevue's Special Pathogens Program. Dr. Mukherjee is an Associate Professor of Medicine in the Division of Pulmonary, Critical Care and Sleep Medicine at the NYU Grossman School of Medicine. Dr. Mukherjee serves as co-Principal Investigator for NETEC, as a steering committee member for the National Special Pathogens System of Care, and as an executive member of the Task Force for Mass Critical Care. His research interests include special pathogen preparedness and mass critical care. Vikramjit Mukherjee completed his medical training at Armed Forces Medical College, India, before arriving in the United States. Here, he completed his residency and chief residency at Georgetown University/Washington Hospital Center and fellowship and chief fellowship in Pulmonary and Critical Care Medicine at New York University Medical Center. Following completion of training in 2015, he joined faculty in the Division of Pulmonary, Critical Care and Sleep Medicine at New York University Grossman School of Medicine. Host Jill Morgan, RN Emory Healthcare, Atlanta, GA Jill Morgan is a registered nurse and a subject matter expert in personal protective equipment (PPE) for NETEC. For 35 years, Jill has been an emergency department and critical care nurse, and now splits her time between education for NETEC and clinical research, most of it centering around infection prevention and personal protective equipment. She is a member of the Association for Professionals in Infection Control and Epidemiology (APIC), ASTM International, and the Association for the Advancement of Medical Instrumentation (AAMI). Resources About NETECNETEC LeadershipTransmission Interrupted PodcastNational Special Pathogen System (NSPS)NETEC Resource Library About NETEC A Partnership for Preparedness The National Emerging Special Pathogens Training and Education Center's mission is to set the gold standard for special pathogen preparedness and response across health systems in the U.S. with the goals of driving best practices, closing knowledge gaps, and developing innovative resources. Our vision is a sustainable infrastructure and culture of readiness for managing suspected and confirmed special pathogen incidents across the United States public health and health care delivery systems. For more information visit NETEC on the web at www.netec.org. NETEC Consultation Services Assess and Advance Your Readiness for Special Pathogens with Free, Expert Consulting. NETEC offers free virtual and onsite readiness consulting to help health care facilities and EMS agencies prepare for special pathogen events. Our targeted support services are delivered by experts selected and assigned to each inquiry based on the unique needs of your organization. Have a question? Ask a NETEC expert. For more information visit: netec.org/consulting-services.

In episode 248 of America Adapts, host Doug Parsons is joined by Professor Mark Nevitt of Emory University School of Law to unpack the repeal of the Clean Air Act's Endangerment Finding and what it means for climate governance in the United States. Long considered the legal backbone of federal climate regulation, its rescission raises fundamental questions about agency authority, the role of the courts, and the durability of federal climate policy. Mark explains the legal theory behind the repeal, how it intersects with Supreme Court precedent, and what likely comes next in federal court. The conversation also explores the practical implications of regulatory instability — from increased climate litigation to the shifting balance between federal, state, and local responsibility. For listeners working in adaptation, public policy, infrastructure, law, or risk management, this episode offers a clear look at how legal shifts at the federal level can reshape the broader climate landscape — and why adaptation efforts must continue regardless of political volatility. Transcript for this episode here.  Key Themes Covered in This Episode What the Endangerment Finding actually did under the Clean Air Act Why Massachusetts v. EPA mattered The legal basis for the repeal How the repeal affects federal climate regulation The role of the Supreme Court and administrative law What happens next in federal court More emissions and rising adaptation costs States and cities filling the federal vacuum The growing role of climate litigation Adaptation continuing — but in a more fragmented system Previous appearances by Mark Nevitt on America Adapts Destroy, Rebuild, Repeat: How to Break the Climate Disaster Cycle with Mark Nevitt Climate Change and the Legal System: Why the U.S. Constitution Needs to Adapt with Law Professor Mark Nevitt Climate Adaptation Predictions for 2025: What the Experts Say For Educators & Students The structure and limits of federal agency authority The interaction between executive action and judicial review How Supreme Court doctrine reshapes environmental governance Federalism and the division of climate authority between states and Washington Legal uncertainty and its impact on infrastructure and long-term planning Climate governance in periods of institutional instability The evolving role of courts in climate policy disputes Risk management when regulatory frameworks shift abruptly Professors are welcome to assign this episode or excerpts in syllabi. Who Should Listen to This Episode Climate adaptation and resilience professionals navigating shifting federal policy State and local government officials responsible for long-term planning Urban and regional planners integrating climate risk into infrastructure decisions Insurance, reinsurance, and financial sector professionals assessing regulatory volatility Corporate risk, legal, and strategy teams tracking climate governance shifts Environmental law and public policy scholars following administrative law developments Funders and foundations evaluating the durability of climate investments Climate communicators explaining governance instability to broader audiences   ClimateTech Connect Conference Mentioned in the Episode! ClimateTech Connect Registration Use code: AAVIP for 25% discount off ticket prices   Support for America Adapts helps make episodes like this possible, including more international conversations on how adaptation is unfolding globally. All donations are now tax deductible! Check out the America Adapts Media Kit here! Subscribe to the America Adapts newsletter here. Listen to America Adapts on your favorite app here!   Facebook, Linkedin and Bluesky: https://www.facebook.com/americaadapts/ https://bsky.app/profile/americaadapts.bsky.social https://www.linkedin.com/in/doug-parsons-america-adapts/ Doug Parsons and Speaking Opportunities: If you are interested in having Doug speak at corporate and conference events, sharing his unique, expert perspective on adaptation in an entertaining and informative way, Now on Spotify! List of Previous Guests on America Adapts Follow/listen to podcast on Apple Podcasts. The 10 Best Sustainability Podcasts for Environmental Business Leadershttps://us.anteagroup.com/news-events/blog/10-best-sustainability-podcasts-environmental-business-leaders For more information on this podcast, visit the website at http://www.americaadapts.org and don't forget to subscribe to this podcast on Apple Podcasts.   Podcast Music produce by Richard Haitz Productions Write a review on Apple Podcasts ! America Adapts on Facebook!   Join the America Adapts Facebook Community Group. Check us out, we're also on YouTube! Subscribe to America Adapts on Apple Podcasts Doug can be contacted at americaadapts @ g mail . com

The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:1. Impact of a Smartwatch Hypertension Notification Feature for Population Screening.JAMA 2026. Discussion by: Guest:Erin Russell, MD Resident - Abington Family Medicine Residency Program Jefferson Health - Abington2. A guide to consumer-grade wearables in cardiovascular clinical care and population health for non-experts. Discussion by: Guest:Neil Skolnik, MDProfessor of Family and Community MedicineSidney  Kimmel  Medical College Thomas Jefferson UniversityAssociate Director - Family Medicine Residency ProgramJefferson Health – Abington3. Enhanced Detection and Prompt Diagnosis of Atrial Fibrillation Using Apple Watch: A Randomized Controlled Trial. Journal of the American College of Cardiology 2026 Discussion by: Guest:Jessica Stieritz, MD Resident - Abington Family Medicine Residency Program Jefferson Health - AbingtonMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. This Podcast Episode does not offer CME/CE Credit. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Dr. Patel is the Chief of Cardiology at Vitruvian Health and a board-certified interventional and structural cardiologist. He attended medical school at the Emory University School of Medicine in Atlanta, Georgia, and completed his residency training in internal medicine at the University of California San Francisco in San Francisco, California. He earned his Master in Business Administration degree at Northwestern University-Kellogg School of Management in Evanston, Illinois.He also completed his fellowships in cardiology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois, and then further trained in structural and interventional cardiology at the Emory University School of Medicine in Atlanta, Georgia.https://vitruvianhealth.com/services/heart-vascular

Dr. Patel is the Chief of Cardiology at Vitruvian Health and a board-certified interventional and structural cardiologist. He attended medical school at the Emory University School of Medicine in Atlanta, Georgia, and completed his residency training in internal medicine at the University of California San Francisco in San Francisco, California. He earned his Master in Business Administration degree at Northwestern University-Kellogg School of Management in Evanston, Illinois.He also completed his fellowships in cardiology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois, and then further trained in structural and interventional cardiology at the Emory University School of Medicine in Atlanta, Georgia.https://vitruvianhealth.com/services/heart-vascular

Dr. Patel is the Chief of Cardiology at Vitruvian Health and a board-certified interventional and structural cardiologist. He attended medical school at the Emory University School of Medicine in Atlanta, Georgia, and completed his residency training in internal medicine at the University of California San Francisco in San Francisco, California. He earned his Master in Business Administration degree at Northwestern University-Kellogg School of Management in Evanston, Illinois.He also completed his fellowships in cardiology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois, and then further trained in structural and interventional cardiology at the Emory University School of Medicine in Atlanta, Georgia.https://vitruvianhealth.com/services/heart-vascular

In this throwback episode honoring National Women Physicians Day, host Shikha Jain, MD, with Physicianary's Hansa Bhargava, MD, and Mend the Gap's Dagny Zhu, MD, discuss the evolution of empowering yourself and others and advocacy with a panel of guests. ·       Intro 0:32 ·       What does it mean to empower women in medicine, and what are the ways that we can really empower others to achieve the things that they may not see for themselves?  1:37 ·       What are some ways in which you have empowered or hope to empower women in medicine? Are there tips or skills that have worked well?  4:41 ·       How have you been empowered by others, or have helped others find their voices?  7:37 ·       Do you agree that the conversation is changing toward a cultural shift in empowerment for women in health care? 12:23 ·       What are some challenges facing advocacy and empowerment? […] What do you do when your advocacy work is not being received or it is a struggle to speak up for someone?  17:10 ·       Emphasizing the importance of communication in advocacy work. 22:23 ·       Intro to Physicianary's part 3 on physician burnout and work-life balance. 22:51 ·       Thanks for listening 23:31 Be sure to listen to Part 1 and Part 3 of Healio's Women In Medicine roundtable discussion, streaming everywhere now! Vineet Arora, MD, MAPP (NAM), is a Herbert T. Abelson professor of medicine, vice dean of education in the biological sciences division and dean for medical education at the University of Chicago Pritzker School of Medicine. She is also an elected member of the National Academy of Medicine. She is a founding member of the 501c3 Women of Impact and advisor to the Women in Medicine Summit. Jennifer Bepple, MD, MMCi, is a double board-certified physician in urology and informatics. She is a member of the American Telemedicine Association, American Urologic Association and American Medical Informatics Association and holds a certification from the American Board of Telehealth and the American Board of AI in Medicine. Hansa Bhargava, MD, is Healio's chief clinical strategy and innovation officer. Listen to her Healio podcast, Physicianary. Shikha Jain, MD, FACP, is a board-certified hematology and oncology physician. She is a tenured associate professor of medicine in the division of hematology and oncology, the director of communication strategies in medicine and the associate director of oncology communication & digital innovation at the University of Illinois Cancer Center in Chicago. Mara Schenker, MD, FACS, FAOA, is an orthopedic trauma surgeon at Grady Memorial Hospital. She is double board certified in orthopedic surgery and clinical informatics. She serves as the chief of orthopedics and associate chief medical information officer.  She is an associate professor of orthopedics at Emory University School of Medicine. She serves on multiple boards for medical and digital technology advisory and sits on major national committees for the American Academy of Orthopaedic Surgeons, AAMC, American College of Surgeons and the Orthopaedic Trauma Association. Dagny Zhu, MD, is a cornea, cataract and refractive surgeon and medical director and partner at NVISION Eye Centers in Rowland Heights, CA. She can be reached on X @DZEyeMD. Listen to her on Healio's Mend The Gap: Equity In Medicine podcast. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Disclosures: The hosts and guests report no relevant financial disclosures.

Many serious medical illnesses are associated with some degree of serum electrolyte abnormality, renal impairment, or both. The neurologist must determine if the patient's neurologic symptoms are related to the renal and electrolyte disturbances or whether a concurrent primary neurologic process is at play. In this episode, Casey Albin, MD, speaks with Eelco F. M. Wijdicks, MD, PhD, FAAN, FACP, FNCS, author of the article "Neurologic Manifestations of Renal and Electrolyte Disorders" in the Continuum® February 2026 Neurology of Systemic Disease issue. Dr. Albin is a Continuum® Audio interviewer, associate editor of media engagement, and an assistant professor of neurology and neurosurgery at Emory University School of Medicine in Atlanta, Georgia. Dr. Wijdicks is a professor of neurology and attending neurointensivist for the Neurosciences Intensive Care Unit at Mayo Clinic in Rochester, Minnesota. Additional Resources Read the article: Neurologic Manifestations of Renal and Electrolyte Disorders Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @caseyalbin Guest: @EWijdicks Full episode transcript available here

The sale is complete for a Walton County, Ga. industrial warehouse that will become a new detention center for U.S. Immigration and Customs Enforcement. Local officials confirmed the purchase of the rural warehouse, located approximately 40 miles east of Atlanta. But Social Circle city officials say they’re against it, and Gareth Fenley, a local organizer with Indivisible Boldly Blue, shares on “Closer Look” how she plans to fight it. Plus, Atlanta area hospitals say their staff and resources are ready to respond to the 300,000 FIFA World Cup visitors expected here this summer. Preparations have been ongoing for months in advance, including a training simulation involving two patients who entered the U.S. with an infectious disease. Doctors from Grady Hospital, Piedmont Hospital and the Emory University School of Medicine join the program to discuss their plan to keep residents and visitors healthy during the games. Then, a new ProPublica report is linking a conservative researcher to the seizure of Fulton County’s election records. The author tells us about Kevin Moncla, who has long accused Fulton County of election fraud.See omnystudio.com/listener for privacy information.

In this episode, we are joined by Dr. Loren Krueger, Associate Professor and Residency Program Director at Emory University School of Medicine. Dr. Krueger shares her path into dermatology, from her training at Duke University and the University of Wisconsin School of Medicine to completing her dermatology residency at NYU, where she served as chief resident. She reflects on her journey into leadership and academic dermatology and offers insight into the Emory Dermatology Residency Program, including advice for students interested in the field and what applicants can expect from training at Emory. We hope you enjoy!Connect with Emory Dermatology and Dr.Krueger:Emory Dermatology Instagram: @emorydermDr. Krueger Instagram : @thecurlmd---DIGA Instagram: @⁠⁠⁠derminterest⁠⁠⁠Today's Host: Shan Francis---For questions, comments, or future episode suggestions, please reach out to us via email at ⁠⁠⁠derminterestpod@gmail.com⁠⁠⁠ ---District Four by Kevin MacLeodLink: ⁠⁠⁠https://incompetech.filmmusic.io/song/3662-district-four⁠License: ⁠https://filmmusic.io/standard-license

The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:1. USDA Dietary Guidelines 2025-2030. Discussion by: Guest:Phillip Leiberman, MDResident Family Medicine Residency Program Jefferson Health - Abington2. The Effect of Substituting Wate for Artificially Sweetened Beverages on Glycemic and Weight Measures in People With Type 2 Diabetes: The Study of Drinks With Artificial Sweeteners (SODAS), a Randomized Trial – Diabetes Care 2025. Discussion by: Guest:Neil Skolnik, MDProfessor of Family and Community MedicineSidney  Kimmel  Medical College Thomas Jefferson UniversityAssociate Director - Family Medicine Residency ProgramJefferson Health – Abington3. Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation The DECAFRandomized Clinical Trial – JAMA 2025. Discussion by: Guest:Neil Skolnik, MDProfessor of Family and Community MedicineSidney  Kimmel  Medical College Thomas Jefferson UniversityAssociate Director - Family Medicine Residency ProgramJefferson Health – Abington4. Exercise for the Treatment of Depression. Cochrane Database of Systematic Reviews 2026 Discussion by:Guest:Aaron Sutton - Behavioral Specialist Family Medicine Residency ProgramChief Wellness Officer for Graduate Medical Education Jefferson Health – AbingtonMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. This Podcast Episode does not offer CME/CE Credit. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

In today's episode, Neil Iyengar, MD, moderated an OncLive Insights discussion about adverse effect management when using breast cancer therapies targeting the PI3K, AKT, and mTOR pathways. Dr Iyengar is an associate professor in the Department of Hematology and Medical Oncology and co-director of Breast Medical Oncology in the Department of Hematology and Medical Oncology at Emory University School of Medicine; as well as director of Survivorship Services at the Winship Cancer Institute of Emory University in Atlanta, Georgia. He was joined by Heather Moore, CPP, PharmD, a clinical pharmacist practitioner at the Duke Cancer Center Breast Clinic in Durham, North Carolina; and Sarah Donahue, MPH, NP, a nurse practitioner at the University of California San Francisco Health.  In our exclusive discussion, the experts highlighted the importance of early and comprehensive testing (using both tissue and liquid biopsies) for genetic alterations to guide treatment decisions. They also noted strategies for managing diarrhea, including patient education on diet, proactive use of loperamide, and regular monitoring. They also explained that hyperglycemia management should hinge on prophylactic use of metformin or SGLT2 inhibitors, dietary restrictions, and frequent glucose monitoring. Their conversation on rash management included insights about prophylactic antihistamines, patient education on skin care, and involving dermatology for severe cases. Overall, the experts spotlighted the importance of multidisciplinary collaboration and proactive patient education when treating patients with breast cancer.

Clinicians and patients are in a state of prognostic uncertainty when they are unsure about the future course of an illness. By embracing uncertainty while cultivating prognostic awareness, neurologists can serve the critical role of supporting patients and families through the living and dying process. In this episode, Casey Albin, MD, speaks with Robert G. Holloway, MD, MPH, FAAN, author of the article "Managing Prognostic Uncertainty in Neurologic Disease" in the Continuum® December 2025 Neuropalliative Care issue. Dr. Albin is a Continuum® Audio interviewer, associate editor of media engagement, and an assistant professor of neurology and neurosurgery at Emory University School of Medicine in Atlanta, Georgia. Dr. Holloway is the Edward and Alma Vollertsen Rykenboer Chair and a professor of neurology in the department of neurology at the University of Rochester School of Medicine and Dentistry in Rochester, New York. Additional Resources Read the article: Managing Prognostic Uncertainty in Neurologic Disease Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @caseyalbin Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Albin: Hello, this is Dr Casey Albin. Today I'm interviewing Dr Bob Holloway about his article on managing prognostic uncertainty in neurologic disease, which appears in the December 2025 Continuum issue on neuropalliative care. Welcome to the podcast, and please introduce yourself to our audience. Dr Holloway: Hi, Casey, and thank you. Again, my name is Bob Holloway. I'm a clinician and neurologist up in Rochester, New York, and I've been doing both neurology and palliative care for many years. Dr Albin: Well, that's fantastic. And I really wanted to emphasize how much I really enjoyed reading this article. I know that we're going to get into some of the pearls that you offer, but I really want to tell the listeners, like, this is a great one to read because not only does it have sort of a philosophical take, but you also really provide some pragmatic tips of how we can help our patients manage this prognostic uncertainty. But maybe just tell us a little bit, what is prognostic uncertainty? Dr Holloway: Yes, thank you. Well, I think everyone has a sense of what prognostic uncertainty is. And it's just the uncertain futures that we as clinicians and our patients face. And I would just say that a way to summarize it is just, how do we manage the "not yet" of neurologic illness? Dr Albin: I love that. In neurologic illness, there is so much "not yet" and there are so many unknowns. And what I thought was really helpful about your article is you kind of give us three buckets in which we can think about the different types of uncertainty our patients are facing. What are those? Dr Holloway: This is, I think, an area that really is of interest to me, thinking about how to organize the prognostic "not yet" or that landscape. And one way I've tried to simplify it is to think about it as data-centered. And that's the world that we mostly live in as neurologists. That's the probability distributions. We also have kind of system-level uncertainties, and that's the uncertainties that our health system affords for our patients. And then we have, also, the patient-centered uncertainties and the uncertainties that those two prior categories cause for our patients. And that's a big uncertainty that we often don't address. Dr Albin: In reading the article, I was really struck by, we spend a lot of time thinking about data uncertainty. Can we get population-based research? Can we sort of look at prognostication scoring? I live in the ICU, and so we think a lot about these, like, scoring metrics and putting patients into buckets and helping us derive their care based on where their severity index is. And I'm sure that is true in many of the divisions of neurology. But what I did not really appreciate---and I thought you did a really fantastic job of kind of drawing our attention to---is there's a lot of system-centered uncertainty. Can you give us a little bit of examples, like, what is system-based uncertainty? Dr Holloway: I think system-level uncertainties just encompass the practical information gaps that may arise during our healthcare encounter. And a lot of, I think, the uncertainty that our patients face and families, they actually describe it as they feel captive by the uncertainty. And it's just the unknowns, not just what affords from the actual information about the disease and its prognosis in the future, but actually the level of the system, like, who's going to take care of them? How do you manage arranging for nurses to come into the home or all those practical-level uncertainties that the system provides that sometimes we don't do a good job of road-mapping for patients. Dr Albin: Absolutely. Because I feel like we have a little bit of a gap in that often as physicians. Like, the family asks, what will hospice at home look like? Well, you know, that's a question for case management. I think they'll come in and they'll tell you. But it strikes me that that's a real gap of my being able to walk patients through. Will they get home health care? Will they have transportation set up? Will there be a nurse who comes in to check? How often are they available? What's the cost going to be? All of these practical aspects of dealing with an illness that are beyond sort of our scope of knowledge, but probably have a huge practical impact to the patient. Dr Holloway: Without question, every encounter patients wonder about, that kind of future wish landscape that we- all our future-oriented desires and hopes. And so much of that is the practical aspects of our health system, which is often fragmented, kind of unknown, uncertain. And that's a huge source of uncertainty for our patients and families. And then that leads to many other uncertainties that we need to address. Dr Albin: Absolutely. I think another one that we, again, maybe don't spend quite as much time thinking about is this patient-level uncertainty. What's going on there? Dr Holloway: Yeah. So, I think patient-level uncertainty is that uncertainty that they experience when confronted with the two other types of uncertainty: the actual data-centered uncertainty and the system-level uncertainty. And that's that, kind of, very huge kind of uncertainty about what it means for them and their family and their future futures. And that's a source of huge stress and anxiety, and often frankly bordering on dread and fear for our patients and families. That actually gets into very levels of uncertainty that I would call maybe over even in the existential realm. Patient-level uncertainty in the actual existential questions or the fear and the dread or the kind of just unnerving aspect of it is actually even more important to patients than the scientific or data-centered uncertainty that we focus most of our attention on. Dr Albin: Yeah, I think this is, to me, was getting towards that, like, what does the patient care about and how are they coping with what is in many times a really dramatic shift in their life expectancy or morbidity expectations and this sort of radical renegotiation about what it means to have a neurologic illness? And how does that shift their thinking about who they are and their priorities in the world? Is that right? Dr Holloway: One thousand percent, and in fact, I will say---and I think is one of the main take home messages is that, you know, managing prognostic certainty is not an end in itself. It really is to help patients and families adaptively cope to their new and often harsh new reality, that we could help them adapt to their new normal. I think that is one of our main tasks as neurologists in our care teams is to help patients find and ultimately maybe achieve existential or spiritual or well-being even in their new health states. You know, that you certainly often see in the intensive care unit, but we often always see in the outpatient realm as well, and all our other diseases. Dr Albin: I think that's really hard to do. I think those conversations are incredibly difficult and trying to navigate where patients want to be, what would bring meaning, what would bring value. I think many of us struggle to have these pretty real and intense conversations with families about what really is important. And one of the things I really liked about this article is you kind of walk us through some steps that we as clinicians can take to get a little bit more comfortable. Maybe just walk us through, what are some of the things that you have found most helpful in trying to get families and patients to open up about what brings them meaning? How are they navigating this new, really uncertain time in their life? Dr Holloway: Yeah, so I do kind of have a ten-point recommendations of how to help cultivate a more integrated awareness of an uncertain future. I mean, I think the most important thing is actually just recognizing that embracing uncertainty as an amazingly remarkable cognitive tool. I mean, let's face it, uncertainty, when it happens with neurologic illness and disease, is often fearful. It's scary. It kind of changes our world. But on the flip side of it, it's a remarkable cognitive tool that actually can help us find new ways and new paths and new creativity. And I think we can use that kind of opposites to help our patients find new meaning in very difficult situations. So, thinking about uncertainty, kind of being courageous, leaning into it and recognizing that it does create anxieties and fear, but it also can kind of help create new solutions and new ideas to help people navigate. Dr Albin: I was hoping that maybe you could give us an example of, like, how would you do that? If a patient comes in and they're dealing with, you know, a new diagnosis and they're navigating this new uncertainty, what are some of the things that you ask to help them reframe that, to kind of take some of the good about that uncertainty? How do you navigate that? Dr Holloway: One of the other recommendations is actually just resetting the timeline and expectations for these conversations. That it shouldn't be expected that patients should accept their harsh new reality immediately, that it takes time in a trusted environment. And that there's this, like, oscillating nature of hopes and fears and dread, and you've just got to work with them over time. And with time, and once you understand who the patient and family are and understand where they find meaning and where they find, actually, joy in their life, or what actually brings them meaning, you can start recasting their futures into credible narratives in their kind of future landscape in ways that I think can help them enter into their new realities within the, you know, framework of disease management that you can offer them within your healthcare team or your healthcare system or wherever you are in the world and the available resources that you have to offer patients and families. Dr Albin: So, this sounds like a lot to me like active listening and really trying to get to know what is important to the family, what is important to the patient. And I guess probably just creating that space even in that busy clinical environment. Do I have that right? Dr Holloway: You can absolutely do that, right. You know, and honestly, active listening, we are challenged in our busy healthcare system to do this, but I think with the right listening skills and the appropriate ways of paying attention, you can definitely illuminate these possible, kind of future-oriented worlds for patients and help them navigate those new terrains with them. Frankly, I think that's a real new space for us in neurology. We don't think about and train how to create credible narratives for patients and families. We do it on the fly, but I think there's so much more work to do. How do you actually keep, you know, that best-case, worst-case, most likely credible narratives for patients that can help them adapt to their new realities and support them on their new journeys? Dr Albin: I love that best-case, worst-case, most likely case. I find that framework really helpful. But you talk in your article, it's not just about using that best case or worst case or most likely, but it's actually building some forecasting into that and having some real data to kind of support what you're saying. And there's a lot of growth towards actually becoming good as a medical forecaster. Can you describe a little bit, what did you mean by that? Dr Holloway: You're absolutely right. I think, actually, one of the skillsets of becoming and managing prognostic uncertainty is actually becoming a skilled medical forecaster. And it's a really tall order. So, we've got to be both good medical forecasters as well as helping patients adaptively cope to their new reality. But the good medical forecasting is actually now going more quantitative in thinking about the data that's available to help think about the important outcomes for patients and families and then predicting what their probabilities are so you can shape those futures around. So, yes, we do have to have an open mindset. We do have to actually look at the data that's available and actually think about, what are those long-term probabilities and outcomes? And we can be honest about those and even communicate them with families. But it's a really good skill set to have. Dr Albin: Yeah. This to me was a little bit about, how do you bring in the data knowledge that we try to get over time as we develop our expertise? You're developing not just a reliance on population-based data, but in my experience, I have seen this. And that sort of ability to kind of look at the patient in front of you, think about the big picture, but also a little bit about their unique medical comorbidities or prior life experiences. So, some of that database knowledge, and then bringing in and getting to know what is important to the patient. And so, sort of marrying that data-centric/patient-centric mindset. Dr Holloway: I love it. I guess the other way of saying that, too, is we need to think with precision, but communicate in narratives. And it's okay to gently put more precise estimates on our probability predictions with patients and families, what we think is the most likely case, best and worst case. Because patients and families want us to be more precise. We often shy away from it, but- so, it's okay to think in precisions, but we've got to put those in narratives in the most likely, best-, and worst-case scenarios. And don't be afraid if you think in terms of ninety percents, ten percents, fifty percents; most patients and families don't mind that. And what they're telling us is they actually want to hear that, if you are comfortable talking in those terms. Dr Albin: Yeah, absolutely. And giving a sense of the humility to say, like, this is my best guess based on medical data and my experience, I would say, but again, none of us have a crystal ball. And I do think families, as long as you're sort of couching your expectations into the sort of imperfect, but I'm doing my best, really appreciate that. Dr Holloway: They totally do all the time. Just say, I simply don't know for certain, but these are my best estimates. That's a good way of just phrasing that. Dr Albin: Yeah. So powerful. I don't know for certain. And then I wanted to just kind of close out, because there's this one term that you use that I thought was so interesting. And I wanted you to kind of tell our listeners a little bit about what you mean here, which is that, when you're actively open-minded, you're using this, quote, "dragonfly eyes." What do you mean by that? Dr Holloway: So, the dragonfly eyes, as you know, they can look at three sixty around them and they just, they move in all directions. Being actively open minded, I guess the biggest example I would say is, I don't like the term prognostic discordance, which means that there's a difference of subjective estimates of prognosis between patients and families. Being openly minded is actually embracing the potential information that the family has about prognosis and incorporating that into your estimates. So, I wouldn't say it's discordances, per se; I think being really actively open-minded is taking that all in and utilizing that as, you know what, they know more than you do about the patient and their loved ones, and they may have insights that can inform your best estimates of prognosis. So, the true dragonfly prognosticator actually is one who embraces and doesn't consider it discord, but considers it kind of new, useful information that I just need to weigh in so I can help the family in my best professional way in terms of developing a prognosis, whatever the condition may be. Dr Albin: I can imagine this is just so challenging and something that takes a long time to sort of perfect all of this. I think you say right below that, you need a growth mindset to do this because it is hard, and it's going to take an active participation and an active desire to get better at these conversations with our families. Dr Holloway: One thousand percent. You are so right that it takes time, effort, and not feeling like you're being challenged, but that actually you are including them in your entire body of knowledge, that you're just- it's part of all you're collecting. And even, I was on service last week, and I talked to residents and students about that very issue. It's like take their prognosis. And someone who came in, we thought CJB, very sad, tragic case, but we were thinking about what the future may look like and how do we actually work with the family who had very what we thought was unrealistic expectations. I said, well, no, this is not discordance. This is just useful information that we can take understand where they're coming from and incorporate that into the ways we want to build relationships, build trust, and over time we'll get to a point where we hopefully can work with them and have them have that fully integrated awareness of their future. Dr Albin: Yeah, that's beautiful. It really is this ongoing negotiation that really requires so much listening, understanding, and then obviously information and expertise about the data that we're presenting and the likelihood outcome, recognizing that there's a lot of uncertainty in all of this. Which, you know, again, this is kind of a 360 talk. At every level there is uncertainty, and that's what makes it so hard. Dr Holloway: Yeah, you're absolutely right. And actually, even in the article I kind of used the term radical uncertainty as that, no matter how resolvable all this uncertainty is, there will always still remain that radical element of our existence which we have to actually incorporate and be prepared for. And actually, not only of ourselves, but actually for patients and families and helping manage that. Using narratives and credible narratives and kind of ranges of possibilities is the best way to do that in a personalized way. Dr Albin: Well, this has been a fantastic conversation, and I know that we are running a bit short on time. So, as we wrap up and you think about this topic, are there any key take-home messages that you hope our listeners will walk away with? Dr Holloway: I think one main emphasis is that despite all the successes we feel we have in neurology, is that we all have to recognize that prognostic uncertainty is just going to increase in the future. But this is going to be for several reasons. One is that, just, the illness uncertainty of all of our great therapies are just going to be creating more uncertainty for the future. And precision medicine is paradoxical, and that actually it creates more uncertainty. So, I think we need to be prepared that we have to manage prognostic uncertainty better, because it's definitely going to increase. And two, it's what I said earlier, is that actually managing prognostic uncertainty is not an end to itself. It's actually helping patients and families adapt to their new and sometimes harsh new reality and actually help them to ultimately get to a place where maybe either their condition is neither dreaded, but actually they can accept it as their new reality and actually achieve some sort of existential well-being and existential health. I think that we have a lot more to emphasize in this area. And for far too long, we've focused on the certainty aspect of our field and not enough on the uncertainty in the world of medicine to help our patients and families. Dr Albin: And gosh, isn't there just so much uncertainty? And I think this has been beautiful. So, thank you again for coming and sharing your expertise. Dr Holloway: Thank you very much. It's been a pleasure. Dr Albin: For all of our listeners out there, this is a truly fantastic article, and I would just like to direct you to going to read the cases because not only do the cases offer a little bit of practical advice, but there's one that's actually sort of a philosophical discussion about, what does it mean to be alive and confront death? There's some beautiful artwork that's featured as well. So this is just a really unique article, and I'm excited for our listeners to have a chance to check it out. So again, today I've been interviewing Dr Bob Holloway about his article on managing prognostic uncertainty in neurologic disease, which appears in the December 2025 Continuum issue on neuropalliative care. Be sure to check out Continuum Audio episodes from this and other issues. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

This episode of Transmission Interrupted dives deep into the fascinating world of seasonal special pathogens, exploring the reasons why certain infectious diseases emerge and surge at specific times of year. Host Jill Morgan is joined by Dr. Susan McLellan and Dr. Lindsay Busch, two experts in infectious diseases and biocontainment, for a captivating discussion on Nipah virus and Lassa fever. From emergency rooms filled during flu season to the quirky, unexpected ways that bats and rodents drive outbreaks in far-off regions, our guests break down what makes these pathogens so unique. Learn how cultural practices, environmental changes, and climate can influence the risk of transmission, and why understanding "One Health" and anthropology is vital for outbreak control. Perfect for clinicians, public health enthusiasts, and anyone curious about how diseases move through populations, this episode offers practical insight into recognizing risk factors, travel histories, and how global disease surveillance impacts communities everywhere. Packed with real-world stories, unexpected facts, and expert advice for spotting and responding to these high-consequence infections, this episode is not to be missed. Subscribe to Transmission Interrupted for more episodes and resources: netec.org/podcast Questions or ideas for future shows? Email us at info@netec.org. Guests Lindsay Busch, MD Assistant Professor, Medicine, Emory University School of Medicine Associate Medical Director, Emory University Serious Communicable Diseases Unit Critical Care Liaison, Emory Serious Communicable Diseases Program Susan McLellan MD, MPH Director, Special Pathogens Excellence in Clinical Treatment, Readiness, and Education (SPECTRE) University of Texas Medical Branch Host Jill Morgan, RN Emory Healthcare, Atlanta, GA Jill Morgan is a registered nurse and a subject matter expert in personal protective equipment (PPE) for NETEC. For 35 years, Jill has been an emergency department and critical care nurse, and now splits her time between education for NETEC and clinical research, most of it centering around infection prevention and personal protective equipment. She is a member of the Association for Professionals in Infection Control and Epidemiology (APIC), ASTM International, and the Association for the Advancement of Medical Instrumentation (AAMI). Resources Lassa Fever resources at NETECNipah resources at NETECTransmission Interrupted PodcastNETEC YouTubeSign up for NETEC's Email Newsletter About NETEC A Partnership for Preparedness The National Emerging Special Pathogens Training and Education Center's mission is to set the gold standard for special pathogen preparedness and response across health systems in the U.S. with the goals of driving best practices, closing knowledge gaps, and developing innovative resources. Our vision is a sustainable infrastructure and culture of readiness for managing suspected and confirmed special pathogen incidents...

Nicole Moorman, a top criminal defense attorney based in Atlanta, walks through what it's really like working inside the justice system — from defending people in serious felony and federal cases to the pressure of high-stakes trials and courtroom strategy. Born in Chicago and trained in criminal justice and law at Southern Illinois University, Troy University, and Emory University School of Law, Nicole brings a unique perspective shaped by years of legal experience and time spent as a probation officer and task force agent before becoming a lawyer. She explains how she approaches complex defenses, the ethical challenges defenders face, and why protecting the rights of the accused matters so deeply, with insights drawn from real cases and her career as one of Georgia's most respected advocates. _____________________________________________ #CriminalDefenseAttorney #TrueCrime #JusticeSystem #LegalReality #DefenseAttorney #RealStories #YouTubePodcast #lawandcrime _____________________________________________ Thank you to FACTOR for sponsoring this episode: Head to https://factormeals.com/lockedin50off and use code lockedin50off to get 50% off your first Factor box PLUS free breakfast for 1 year. Offer only valid for new Factor customers with code and qualifying auto-renewing subscription purchase. Make healthier eating easy with Factor. _____________________________________________ Connect with Nicole Moorman: Instagram: https://www.instagram.com/_kingcole_/?hl=en Website: https://moorman-law.com/ _____________________________________________ Hosted, Executive Produced & Edited By Ian Bick: https://www.instagram.com/ian_bick/?hl=en https://ianbick.com/ Shop Locked In Merch: http://www.ianbick.com/shop _____________________________________________ Timestamps: 00:00 Intro: Cooperation, Ethics & the Reality of the Justice System 00:27 Nicole Mormon's Childhood, Family & Early Influences 01:33 Education Path That Led to Criminal Justice 05:44 Why Nicole Chose Criminal Justice 07:01 From Chicago to Atlanta: Becoming a Probation Officer 11:10 First Cases as a Probation Officer & Reality Shock 13:37 Probation, Pretrial Supervision & System Flaws 14:40 Leaving Probation to Attend Law School 16:16 Law School Life & Interning at the DA's Office 17:55 Inside the DA's Office: What Prosecutors Really See 19:58 Starting Her Legal Career & Going Solo 20:35 First Trials, Stress & Emotional Pressure 22:00 Attorney-Client Relationships & Ethical Boundaries 23:38 Choosing Clients & Managing Expectations 24:43 Judges, Prosecutors & Fairness in the Courtroom 26:22 Prosecutor vs Defense Relationships Explained 27:16 State vs Federal Cases: Key Differences 28:53 Target Letters, Indictments & Bond Hearings 31:00 Trial Strategy: When to Push Forward or Slow Down 32:54 Preparing for Trial Mentally & Physically 35:23 Balancing Personal Life During High-Stress Trials 37:32 Trial Tactics, Verdicts & Jury Psychology 40:31 Jury Behavior in High-Profile Cases 42:27 Jury Selection & the Role of Consultants 43:32 Critical Trial Moments & Penalties for Going to Trial 44:53 Sentencing, Judges & the Appeals Process 47:17 Custody Status, Bond & House Arrest Explained 50:48 Biggest Client Misconceptions & Money in the System 53:00 Political Influence on Prosecutors & Charging Decisions 55:46 Diversion Programs, Plea Options & Fairness 57:00 Cooperation, Plea Deals & Informants 59:02 Plea Agreements, Testifying & Subpoenas 01:01:31 Trial Delays & Frustrations with the System 01:02:20 What Nicole Would Change About the Justice System 01:03:10 Advice to Her Younger Self 01:04:28 Life Lessons from a Legal Career 01:05:56 Final Thoughts & Closing Message Learn more about your ad choices. Visit megaphone.fm/adchoices

For two-and-a-half centuries, the United States has faced a challenging world. Some of its responses have made Americans proud. Others have not. CFR asked members of the Society for Historians of American Foreign Relations what they considered the best and worst U.S. foreign policy decisions. In this episode, panelists discuss the results of the project and the evolution of America's role in the world.   Host: David M. Rubenstein, Cofounder and Cochairman, The Carlyle Group; Chairman, Board of Directors, CFR   Guests: Mary L. Dudziak, Asa Griggs Candler Professor of Law, Emory University School of Law; CFR Member   James M. Lindsay, Mary and David Boies Distinguished Senior Fellow in U.S. Foreign Policy, CFR   Christopher M. Nichols, Wayne Woodrow Hayes Chair in National Security Studies and Professor of History, The Ohio State University   Want more comprehensive analysis of global news and events sent straight to your inbox? Subscribe to CFR's Daily News Brief newsletter.   To keep tabs on all CFR events, visit cfr.org/event. To watch this event, please visit it on our YouTube channel: America at 250 Series: The Best and Worst Decisions in U.S. Foreign Policy

When addressing obesity in the clinic, it's common to ask patients to focus on food and exercise. But what if we think upstream of the clinical problem and consider the environments, habits and systems that shape health from the very beginning? In this episode, we sit down with an expert whose research has focused on building resilience against obesity starting early in life. From family dynamics to school and community initiatives, the picture of prevention is complex.  Shari Barkin, MD, is the Pediatrician in Chief at Children's Healthcare of Atlanta. She is also the Chair of the Department of Pediatrics, Executive Director of the Pediatric Institute, and the George W. Brumley Jr. Endowed Professor of Pediatrics at Emory University School of Medicine.  Some highlights from this episode include: How to influence eating behaviors in the first six months of life  The role of community involvement and partnerships in preventing childhood obesity  Translating research into practical strategies  Strong communication methods to engage families successfully  This episode is underwritten by Ovintiv, a proud philanthropic supporter of Charting Pediatrics and the Children's Hospital Colorado Foundation. Ovintiv recognizes that their responsibility begins in the communities where they live and work. They are committed to giving back and building safer and more resilient communities. Ovintiv's generous support has made a monumental difference for our patients and families, from enhancing health outcomes to reducing health disparities.  For more information on Children's Colorado, visit: childrenscolorado.org. 

In this inspiring episode of the Emory University series on Nurse Converse, host Dr. Everett Moss II, CRNA, sits down with three powerful voices from the Emory University School of Nursing—Dr. Beth Ann Swan, Dr. Shawana Moore, and recent graduate Sofi Igyan—to unpack one of the most misunderstood words in nursing: power.Together, they challenge the idea that power is something loud, aggressive, or purely positional. Instead, they explore power as the ability to influence change, whether you're an academic leader, an advanced practice nurse, or a new graduate stepping into the profession for the first time.Listeners will hear:Why power is deeply personal and often situational—shifting with the room you're in, the role you hold, and how others perceive you.How humility and silence can be profound sources of strength, including the concept of the “silent storm” and the impact of knowing when not to speak.The student and new-graduate perspective on power—how embracing agency, mentorship, and opportunities can transform the nursing school and early-career experience.The role of mentorship in cultivating influence and the responsibility to lift others as you rise.How storytelling and social media can serve as powerful platforms when nurses share lived experiences and credible information.Practical advice for nurses at every stage—from flowing like water through challenges, to embracing new opportunities, to navigating imposter syndrome.From redefining influence to owning your voice at any stage of a career, this conversation highlights the many forms of power nurses hold—and how harnessing that power can shape both individual careers and the future of the profession.>>8 Keys to Cultivating Power in Your Nursing CareerJump Ahead to Listen: [00:02:19] Understanding power and influence in nursing [00:04:43] Navigating personal power and professional presence [00:10:15] Influence within nursing's power structures [00:14:32] Elevating student confidence and empowerment [00:20:17] How nursing students shape conversations online [00:21:24] Examining influencers and credibility in nursing [00:26:01] Storytelling as a catalyst for impact [00:30:09] Mentorship as a foundation for future leaders [00:37:01] Staying open to unexpected opportunities [00:40:05] Adapting and “flowing like water” in your career [00:42:15] Growth through professional and personal challenges [00:47:00] Books and ideas that inspire empowered nursing practice For more information, full transcript and videos visit Nurse.org/podcastJoin our newsletter at nurse.org/joinInstagram: @nurse_orgTikTok: @nurse.orgFacebook: @nurse.orgYouTube: Nurse.org

  Episode description: We continue our campaign to #EndNeurophobia, with the help of Dr. Aaron Berkowitz. This time, Sarah presents a case to Sebastian and Vijay.  Sarah Blaine (@sarahkblaine) Sarah Blaine is an MD/MSc student at Emory University School of Medicine applying into neurology residency. She isfrom SouthernCalifornia and went to UC Berkeley for her undergraduate… Read More »Episode 435: Neurology VMR – Weakness and numbness

Guest: Rachel Conrad, MA, CCC-SLPEarn 0.10 ASHA CEU for this episode with Speech Therapy PD: https://www.speechtherapypd.com/courses/embracing-lived-experiencesIn the first episode of 2025, Michelle is joined by Jaclyn Pederson, MHI, CEO of Feeding Matters, and William Sharp, PhD, Director of Children's Multidisciplinary Feeding Program (Atlanta, GA) and Professor at Emory University School of Medicine, to lay the foundation for a year of combining passion, advocacy, and learning. These guests share their expertise and highlights from a recent journal publication on how the diagnoses of “Pediatric Feeding Disorder” and “Avoidant Restrictive Feeding Intake Disorder” are individualistic while simultaneously overlapping to capture the unique needs of the little ones on our caseloads. Additionally, they share practical insight into the roles and responsibilities of various team members, such as the SLP and the psychologist, in evaluating and treating these little ones as part of an interprofessional practice team.About the Guest: Rachel Conrad, MA, CCC-SLP, is the owner of Bite and Bloom Therapy, LLC, under The Mindful Collective, where she specializes in pediatric feeding and swallowing, ARFID, AAC, and sensory-based therapy. She serves as the Chair of the Feeding Matters Research Consortium, a patient- and family-centered research initiative partially funded by the Patient-Centered Outcomes Research Institute (PCORI). Rachel brings a unique perspective to her work, combining her professional expertise with her lived experience of pediatric feeding differences and ARFID. She collaborates with The Village, a perinatal and eating disorder provider group, and participates in national advocacy and education initiatives to improve early intervention and interdisciplinary care for children with feeding differences. Rachel has delivered presentations and talks on best practices for evaluating and treating medically complex children with feeding and swallowing disorders. She is passionate about creating spaces where patients and families feel truly heard, seen, and valued in discussions about feeding differences. She is a member of the American Speech-Language-Hearing Association (ASHA) and the Kansas Speech-Language-Hearing Association (KSHA) and is committed to advancing awareness, research, and best practices in pediatric feeding and swallowing. Rachel bridges the gap between research, clinical practice, and lived experience to support children and families navigating feeding differences.Show Notes:Bite & Bloom Therapy: https://www.mindfulcollectivegroup.com/rachel-conradFeeding Matters: https://www.feedingmatters.orgFind Assistance: https://www.findhelp.org

The mental health system didn't start out fair — and in many ways, it still isn't. In this powerful episode, Dr. Nicole Washington sits down with fellow psychiatrist Dr. Leesha Ellis-Cox to unpack the long, painful history that continues to shape the experiences of Black Americans seeking mental health care. From the horrifying “diagnosis” of drapetomania in the 1800s to the Tuskegee Syphilis Study, they trace how mistrust, stigma, and systemic bias became woven into the Black community's relationship with psychiatry.But they don't stop there. Dr. Nicole and Dr. Leesha explore the research showing that Black and Hispanic people are 3 to 4 times more likely to be misdiagnosed with schizophrenia instead of bipolar disorder — a mistake that can derail treatment, worsen symptoms, and put lives at risk.Listener takeaways the historical roots of racial disparities in psychiatric diagnosis why Black Americans are more likely to be misdiagnosed with schizophrenia how stigma and generational trauma shape attitudes toward treatment practical steps to find culturally humble, affirming providers Most importantly, they offer real, actionable advice: how to find culturally affirming care, how to navigate bias in the system, and how Black and other communities of color can break generational silence around mental health. This conversation is validating, eye-opening, and deeply empowering. Listen now!   Our guest, Dr. Leesha Ellis-Cox, affectionately known as Dr. Leesha, is a double board certified child, adolescent, and adult psychiatrist. She earned both her Bachelor of Science and Doctor of Medicine degrees from the University of North Carolina at Chapel Hill and completed her general psychiatry residency training, child and adolescent psychiatry fellowship, and community mental health/public psychiatry fellowship at Emory University School of Medicine in Atlanta. Since 2009, she has lived and worked in Alabama and is the medical director at Central Alabama Wellness, a community mental health center located in metro Birmingham. Our host, Dr. Nicole Washington, is a native of Baton Rouge, Louisiana, where she attended Southern University and A&M College. After receiving her BS degree, she moved to Tulsa, Oklahoma to enroll in the Oklahoma State University College of Osteopathic Medicine. She completed a residency in psychiatry at the University of Oklahoma in Tulsa. Since completing her residency training, Dr. Nicole has spent most of her career caring for and being an advocate for those who are not typically consumers of mental health services, namely underserved communities, those with severe mental health conditions, and high performing professionals. Through her private practice, podcast, speaking, and writing, she seeks to provide education to decrease the stigma associated with psychiatric conditions. Find out more at DrNicolePsych.com. Our host, ⁠Gabe Howard⁠, is an award-winning podcast host, author, and sought-after suicide prevention and mental health speaker, but he wouldn't be any of those things today if he hadn't been committed to a psychiatric hospital in 2003.Gabe also hosts Healthline's ⁠Inside Mental Health⁠ podcast has appeared in numerous publications, including Bipolar magazine, WebMD, Newsweek, and the Stanford Online Medical Journal. He has appeared on all four major TV networks, ABC, NBC, CBS, and FOX. Among his many awards, he is the recipient of Mental Health America's Norman Guitry Award, received two Webby Honoree acknowledgements, and received an official resolution from the Governor of Ohio naming him an “Everyday Hero.” Gabe wrote the popular book, "⁠Mental Illness is an Asshole and other Observations⁠," available from Amazon; signed copies are available ⁠directly from the author⁠ with free swag included! To learn more about Gabe, or to book him for your next event, please visit his website, ⁠gabehoward.com⁠. Learn more about your ad choices. Visit megaphone.fm/adchoices

From November 6, 2024: For today's special episode, Lawfare General Counsel and Senior Editor Scott R. Anderson held a series of conversations with contributors to a special series of articles on “The Dangers of Deploying the Military on U.S. Soil” that Lawfare recently published on its website, in coordination with our friends at Protect Democracy.Participants include: Alex Tausanovitch, Policy Advocate at Protect Democracy; Laura Dickinson, a Professor at George Washington University Law School; Joseph Nunn, Counsel in the Liberty and National Security Program at the Brennan Center; Chris Mirasola, an Assistant Professor at the University of Houston Law Center; Mark Nevitt, a Professor at Emory University School of Law; Elaine McCusker, a Senior Fellow at the American Enterprise Institute; and Lindsay P. Cohn, a Professor of National Security Affairs at the U.S. Naval War College. Together, they discussed how and why domestic deployments are being used, the complex set of legal authorities allowing presidents and governors to do so, and what the consequences might be, both for U.S. national security and for U.S. civil-military relations more generally.To receive ad-free podcasts, become a Lawfare Material Supporter at www.patreon.com/lawfare. You can also support Lawfare by making a one-time donation at https://givebutter.com/lawfare-institute.Support this show http://supporter.acast.com/lawfare. Hosted on Acast. See acast.com/privacy for more information.